CUKTECH 25SE Power Bank Makes Its Powerful Debut in Malaysia, Setting a New Benchmark for High-Capacity Fast Charging

CUKTECH 25SE Power Bank Makes Its Powerful Debut in Malaysia, Setting a New Benchmark for High-Capacity Fast Charging




CUKTECH 25SE Power Bank Makes Its Powerful Debut in Malaysia, Setting a New Benchmark for High-Capacity Fast Charging

KUALA LUMPUR, Malaysia, Feb. 28, 2026 (GLOBE NEWSWIRE) — CUKTECH, a leading innovator in intelligent charging solutions, today announced the official launch of its highly anticipated CUKTECH 25SE Power Bank in the Malaysian market. Officially available starting 26 February 2026, this new offering combines an impressive 120W output with a massive 25,000mAh capacity*, and is now available at an exclusive launch price of RM124, setting a new benchmark for value in Malaysia’s high-capacity fast charging segment.

image1

Positioned as the “value king of high-capacity fast-charging power banks,” the CUKTECH 25SE perfectly addresses Malaysia’s growing need for efficient and reliable power solutions. Its core strength lies in the substantial 25,000mAh capacity. On a full charge, it can power up a smartphone over four times or provide a full additional charge for a thin-and-light laptop, making it the ideal companion for long-distance travel, dormitory power outages, extended library sessions, and various other scenarios.

Understanding that Malaysian users typically own devices from multiple brands, the CUKTECH 25SE incorporates Adaptive Fast Charging (ADC) technology. It offers broad compatibility with major fast-charging protocols, including Xiaomi’s 120W HyperCharge, as well as PD 100W, and PPS 100W. Whether rapidly topping up a smartphone or powering high-demand devices like laptops or even drone batteries, it effortlessly meets the needs of diverse scenarios, from daily commutes to outdoor photography.

Designed with user convenience in mind, the CUKTECH 25SE features a built-in 6A Cable. This integrated cable supports up to 120W output and 100W input, effectively eliminating the common hassle of carrying and managing separate charging cables.

CUKTECH is dedicated to providing global consumers with high-quality, cost-effective intelligent charging solutions. Always prioritizing user needs, the company continues to expand its product portfolio. CUKTECH firmly believes that premium technology shouldn’t be a luxury, but an everyday essential accessible to every user in Malaysia.

To celebrate the new product launch and in conjunction with the upcoming 3.3 Mega Sales, the CUKTECH 25SE Power Bank is now officially available for purchase on CUKTECH’s official stores on Shopee and Lazada in Malaysia. For users seeking both quality and performance, this is the perfect time to acquire this versatile and powerful mobile power solution.

*25,000mAh refers to the cell capacity

Victor Li
lijiayuan@cuktech.net
https://cuktech.com

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f62ac1fd-6d3e-48cf-b588-b1a4fff86860

Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services

Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services




Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services

BEIJING, Feb. 28, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has signed a strategic collaboration agreement with Youcare Pharmaceutical Group (悦康药业集团 or “Youcare”) (SH: 688658), a leading integrated pharmaceutical enterprise in China. The partnership aims to accelerate the digital transformation and enhancement of chronic disease services through the application of artificial intelligence (“AI”).

Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance

Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance

The agreement outlines a joint commitment to applying AI across various chronic care scenarios and upgrading full-lifecycle health management solutions. The two companies plan to build a more accessible, efficient, and precision-oriented healthcare service ecosystem, supporting the national shift in China’s chronic disease management model toward greater digitalization and specialization.

As China’s chronic disease prevention and control system enters a critical stage of digital transformation, industry participants are shifting from a drug treatment-centered model to a patient-centered healthcare approach. In response, Fangzhou has developed its “AI + H2H (Hospital-to-Home)” smart healthcare ecosystem, embedding AI capabilities across consultation, medication management, and post-treatment follow-up services. Fangzhou has launched a series of AI-powered tools, including an AI physician assistant, AI medication assistant, AI health manager, and AI content-generation engine, designed to improve operational efficiency and patient experience. In 2026, Fangzhou plans to deepen AI deployment across every stage of the chronic disease management value chain.

Under the new partnership, the companies will pursue two primary areas of collaboration:

  1. Co-development of Digital Systems: Integrating Youcare’s innovative pharmaceutical products and medical expertise with Fangzhou’s AI-driven service capabilities to create a digitally enabled chronic disease management system
  2. Expansion of Health Management Services: Exploring diversified collaboration models to expand full-cycle health management in key therapeutic areas—such as cardiovascular, infectious disease, and endocrine diseases—leveraging AI to broaden patient access to quality medicines and professional care

Zhou Feng, Chief Strategy Officer of Fangzhou, commented, “The collaboration represents both complementary strengths and a step toward building a new healthcare ecosystem,” adding that the company will continue leveraging its AI technologies, digital operations and patient service capabilities to advance intelligent chronic care systems.

Yu Pengfei, Director and Deputy General Manager of Youcare, stated, “The partnership marks an important move in extending the company’s focus from pharmaceutical supply to comprehensive health services,” adding that collaboration with Fangzhou’s AI-enabled chronic care platform could enhance the accessibility and real-world impact of its innovative therapies.

Both companies said the partnership, combining AI technology, chronic disease services, pharmaceutical innovation and supply chain capabilities, align with China’s broader healthcare objectives, including the “Healthy China 2030” initiative.

About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

About Youcare Pharmaceutical Group
Youcare Pharmaceutical Group (SH: 688658) is one of “the top 100 enterprises of Chinese Pharmaceutical Industry”, founded in 2001, headquartered in Beijing and listed in 2020 (Stock Code: 688658SH), is a large-scale conglomerate integrating the new drug R&D, pharmaceutical manufacture, distribution & sales as well as international business.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e345ff10-3610-40af-9dfd-3ad193ee8206

Sugar Harmony Drops Claims Evaluated: 2026 Report on SugarHarmony Liquid Formula Ingredients, Pricing, and What Consumers Should Verify Before Purchasing

Sugar Harmony Drops Claims Evaluated: 2026 Report on SugarHarmony Liquid Formula Ingredients, Pricing, and What Consumers Should Verify Before Purchasing




Sugar Harmony Drops Claims Evaluated: 2026 Report on SugarHarmony Liquid Formula Ingredients, Pricing, and What Consumers Should Verify Before Purchasing

A 2026 informational consumer evaluation of Sugar Harmony Drops marketing claims, ingredient research context, liquid supplement format considerations, pricing structure, and what consumers should verify before purchasing

Tallmadge, OH, Feb. 27, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional before starting supplements. If you purchase through links in this article, a commission may be earned at no additional cost to you.

This article is an informational overview and does not constitute medical, health, or dietary advice. Product details, pricing, and policies referenced below are presented as stated by the company and should be verified directly on the official website before any purchasing decision.

In this report, terms such as “results,” “support,” or “effectiveness” refer strictly to how Sugar Harmony Drops’ marketing materials describe potential outcomes. These terms do not indicate that Sugar Harmony Drops has been clinically proven effective as a finished proprietary formula.

Consumer interest in metabolic wellness supplements has continued to grow in early 2026, particularly among adults managing daily energy fluctuations and looking for alternatives to traditional capsule-based formulations. Many consumers researching this category use phrases such as “blood sugar support supplement” when comparing ingredient lists, terms, and disclaimers. Sugar Harmony Drops is one of the liquid supplement products generating search activity in this space — and with that visibility come practical questions about what’s actually in the formula, how the cited research should be interpreted, and how the pricing and return policies work in practice.

This report does not recommend for or against Sugar Harmony Drops. It evaluates what the company states, what ingredient-level research indicates in published studies, and what is not established at the finished-product level.

Current product details, pricing, and terms can be confirmed by viewing the current Sugar Harmony Drops offer (official Sugar Harmony Drops page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen, particularly if you are currently managing an existing health condition or taking prescription medications.

Sugar Harmony Drops Claims Evaluated 2026 Report on SugarHarmony Liquid Formula Ingredients, Pricing, and What Consumers Should Verify Before Purchasing

What Is Sugar Harmony Drops

Sugar Harmony Drops is a liquid dietary supplement marketed as a wellness support formula containing all-natural ingredients. The company sells it as a daily liquid drop and positions it as a plant-based option for adults interested in metabolic and overall wellness support. The product is distributed by SugarHarmony Research, with payments processed through ClickBank as the authorized retailer.

Per publicly available information, Sugar Harmony Drops is described as containing a blend of natural vitamins and extracts in a liquid format designed for daily use. The company markets the product as suitable for both men and women. Each bottle is listed as containing 2 fluid ounces, which equates to a 30-day supply at the recommended serving size.

Publicly available materials reference a multi-step process that begins with selecting a pricing package, though specific usage instructions beyond daily consumption are not detailed. Marketplace listings associate the product with the brand name Syvor, while the official website operates under the SugarHarmony Research name.

Sugar Harmony Drops is a dietary supplement. Under current federal regulations, dietary supplements are not required to receive FDA approval before being sold. The FDA does not evaluate supplement efficacy claims prior to market entry. The company’s own website includes the standard disclaimer that statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Sugar Harmony Drops Ingredient Profile: What the Product Page Discloses

The official website’s references section lists 32 scientific citations corresponding to ingredients associated with the formula. Referenced ingredients include Gymnema Sylvestre, Chromium Picolinate, Bitter Melon, Cinnamon Extract, Green Tea Catechins, Astragalus Membranaceus, Grape Seed Extract, Forskolin, Korean Ginseng, Ashwagandha, Capsaicin, GABA, L-Carnitine, African Mango, and additional botanicals and amino acids.

Several of these ingredients have been individually studied in published peer-reviewed research for properties related to glucose-related metabolic parameters and general metabolic wellness, depending on study design and participant population. Gymnema Sylvestre has been examined in nutrition research for its potential effects on glucose uptake. Chromium Picolinate has been studied in relation to glucose metabolism, though findings vary across studies and dosages. Cinnamon and Bitter Melon each appear in metabolic health literature with varying degrees of evidence.

The key consideration for anyone evaluating this formula is dosage transparency. The official product page and marketplace listings describe the formula as containing “all natural ingredients” and “maximum strength premium vitamins,” but publicly available materials don’t appear to disclose the specific amount of each individual ingredient per serving.

That matters because published studies on individual compounds often use specific dosage ranges depending on study design. Because Sugar Harmony Drops does not publicly disclose per-ingredient amounts, readers may not be able to compare the formula’s per-serving quantities to the dosing used in individual research studies. This does not establish that the product has or lacks effect — it means ingredient citations cannot be mapped to serving-level amounts based on publicly available labeling.

Marketing Claims: What Is Stated vs. What Can Be Verified

Sugar Harmony Drops is marketed using language that describes the formula as supporting an active lifestyle, containing maximum strength ingredients, promoting overall well-being, and being crafted with carefully selected natural ingredients. Publicly available marketing materials also reference a satisfaction guarantee and describe the product as providing consistent daily use over a full month.

The company’s references section cites 32 published studies from journals including the Journal of Ethnopharmacology, Diabetes Care, and American Journal of Clinical Nutrition. Those are real peer-reviewed publications that examined individual compounds under specific research conditions. But there’s an important distinction to understand before connecting that research to this specific product.

The studies cited examined isolated ingredients at known dosages in controlled research settings. They didn’t evaluate Sugar Harmony Drops as a finished multi-ingredient liquid supplement. Publicly available sources reviewed for this report do not indicate a published clinical study evaluating Sugar Harmony Drops as a finished proprietary formula.

Consumers researching phrases such as “Sugar Harmony Drops blood sugar results,” “does Sugar Harmony work,” “SugarHarmony effectiveness,” or “Sugar Harmony Drops ingredients research” should understand that marketing claims referencing published studies describe ingredient-level findings, not product-level clinical outcomes. That’s standard across the dietary supplement industry, but it’s especially important to understand in this category where consumers may be making health-related purchasing decisions.

This evaluation doesn’t conclude whether Sugar Harmony Drops has or lacks utility as a wellness supplement. It focuses on clarifying how the performance-related marketing language should be interpreted when you’re doing your own research.

Sugar Harmony Drops Pricing and Purchase Structure

According to pricing information published on the official website at the time of this report, Sugar Harmony Drops is presented in multi-bottle packages. The 6-bottle option is listed at $49 per bottle ($294 total) with free shipping and is described as a 180-day supply. The 3-bottle option is listed at $69 per bottle ($207 total) with free shipping and is described as a 90-day supply. The 2-bottle option is listed at $79 per bottle ($158 total) with $9.99 shipping and is described as a 60-day supply.

All purchases are processed through ClickBank. Pricing listed on the official website describes these as one-time purchases.

Consumers considering the 6-bottle package should be aware of a fulfillment detail described in the company’s Terms of Service. Per the published terms, the 6-bottle offer includes an additional fulfillment step: only three bottles are shipped initially, and the remaining three require the buyer to scan a QR code included with the shipment and submit information within 60 days of the original purchase date. Readers should review current terms directly on the official site before selecting this package.

This offer includes an additional fulfillment step described in the Terms of Service. Pricing and availability may change, and consumers can confirm current terms directly on the official site by viewing the current Sugar Harmony Drops offer (official Sugar Harmony Drops page).

Sugar Harmony Drops Refund Policy and 60-Day Guarantee

The company’s published refund policy states that consumers are covered by a 60-day satisfaction guarantee from the date the order is shipped. If you’re unsatisfied within the first 60 days, you can request a full refund by contacting the support team.

The refund process requires returning all bottles — whether empty, full, or partially full — including any bonus or free bottles. Returns must be sent to the company’s Tallmadge, Ohio fulfillment address with a written note including the order ID, full name, address, email, and phone number. The buyer is responsible for return shipping costs and must provide a tracking number. The company states that consumers should contact support before initiating a return. Refund timelines depend on the buyer’s financial institution. Requests can also be initiated through ClickBank’s self-service portal.

Sugar Harmony Drops Marketing Disclosures: What Consumers Should Know

Official marketing materials include messaging that describes the formula as supporting well-being and complementing health journeys. The company’s disclaimer section states that testimonials, case studies, and examples are results forwarded by users and are not intended to represent or guarantee that anyone will achieve the same or similar outcomes.

Consumers should ensure that promotional content they encounter originates from official brand channels. As with many products advertised online, third-party ads or intermediary pages may circulate that do not necessarily reflect the company’s official messaging or current terms. If you discover a product through social media advertising, confirm the details directly on the official website before making a purchasing decision.

The company’s own Terms of Service include standard disclaimers noting that product information is provided on an “as is” basis and that readers should confirm information with other sources and consult healthcare providers.

Understanding the Difference Between Ingredient Research and Product Research

This is one of the most useful things to understand when evaluating any supplement, and it applies broadly — not just to Sugar Harmony Drops.

Some supplements are evaluated in controlled studies as finished formulations, while others cite research on individual ingredients. Publicly available sources reviewed for this report do not indicate a published clinical study evaluating Sugar Harmony Drops as a finished proprietary formula. The research cited on the product website pertains to individual ingredients tested in isolation, often at dosages that may differ from what the liquid formulation delivers.

Knowing this distinction helps clarify what is established at the ingredient level versus what has not been established at the finished-product level. The type of evidence that would confirm product-level outcomes — a controlled trial of the finished formula — hasn’t been publicly located. That’s something to factor into your decision alongside the other information in this report.

How to Evaluate a Supplement Like This Before Buying

Check whether individual ingredient dosages are disclosed. Full-disclosure labeling lets you and your healthcare provider compare what’s in each serving against published research. When specific amounts aren’t listed, consider contacting the manufacturer directly.

Understand the difference between ingredient research and product research. Many supplements reference published studies on individual compounds. Fewer have been tested as finished formulations. Knowing which type of evidence you’re looking at helps set realistic expectations.

Read the terms of service and disclaimer pages. Important information about fulfillment procedures, refund requirements, and how the company characterizes expected results is often found in the fine print rather than on the main product page.

Verify that promotional content comes from official channels. If you discover a product through social media, confirm the details directly on the company’s official website before purchasing. Third-party advertising may not reflect current product terms.

Talk to your healthcare provider first. This is especially important if you’re taking prescription medications or managing an existing health condition. A qualified clinician familiar with your personal medical history is the most reliable resource for evaluating whether any supplement is appropriate for you.

Who Might Consider Sugar Harmony Drops in 2026

Based on how the product is positioned and what’s publicly available about its ingredient profile, Sugar Harmony Drops may appeal to adults who prefer liquid supplement formats. It may also interest consumers exploring natural ingredient-based options as one part of a broader wellness approach that includes balanced nutrition, regular physical activity, and guidance from a healthcare provider.

It may be less suited for consumers who need transparent individual ingredient dosing to make clinical comparisons, those who require medically validated interventions for a diagnosed condition, or anyone expecting significant changes from a single supplement without accompanying lifestyle modifications. As with all dietary supplements, individual outcomes depend on personal health factors, and the FDA does not evaluate supplement efficacy claims before products reach the market.

Consumer Questions About Sugar Harmony Drops

What is Sugar Harmony Drops?

Sugar Harmony Drops is a liquid dietary supplement marketed as a metabolic wellness supplement. Company materials associate the product with glucose-related wellness messaging, and consumers are encouraged to review the company’s disclaimers and terms directly before purchase. It is sold through the official website at getsugarharmony.com and processed through ClickBank. The product is described as containing all-natural ingredients in a liquid drop format designed for daily use.

Is Sugar Harmony Drops FDA approved?

Sugar Harmony Drops is a dietary supplement. Under current federal regulations, dietary supplements do not require FDA approval before being sold. The FDA does not evaluate supplement efficacy claims. The company’s website includes the standard FDA disclaimer that the product is not intended to diagnose, treat, cure, or prevent any disease.

What ingredients are in Sugar Harmony Drops?

Referenced ingredients include Astragalus, Grape Seed Extract, Gymnema Sylvestre, Green Tea Catechins, Cinnamon, Bitter Melon, Chromium Picolinate, Korean Ginseng, Forskolin, Ashwagandha, and others. Individual ingredient dosages per serving do not appear to be publicly disclosed on the product label or website.

Does Sugar Harmony Drops have published clinical trials?

No published clinical trial appears to evaluate Sugar Harmony Drops as a finished proprietary formula. The scientific references on the product website correspond to studies on individual ingredients tested in isolation under specific research conditions.

How long does it take to see results with Sugar Harmony Drops?

Publicly available marketing materials do not appear to specify a defined timeline for expected outcomes. Individual timelines depend on numerous factors including baseline metabolic health, dietary habits, physical activity, and consistency of use. The company’s disclaimer notes that results forwarded by users are not intended to guarantee similar outcomes for all purchasers.

What is the Sugar Harmony Drops refund policy?

The published policy provides a 60-day window from the shipping date for refund requests. All bottles must be returned to the Tallmadge, Ohio address. The buyer covers return shipping and must provide a tracking number. Contact support before initiating returns. Processing timelines depend on the buyer’s financial institution.

How does the 6-bottle fulfillment work?

Per the company’s Terms of Service, the 6-bottle package ships only three bottles initially. The buyer must scan a QR code included with the shipment, submit personal details on a secure webpage, and request the remaining three bottles within 60 days of the original purchase. Failure to complete this process within the stated period may result in forfeiture of the remaining bottles.

Who manufactures Sugar Harmony Drops?

Marketplace listings associate the product with the brand name Syvor, while the official website operates under SugarHarmony Research. The fulfillment address is in Tallmadge, Ohio. Specific manufacturing facility details, including GMP certification status, are not prominently disclosed on the official website.

Is Sugar Harmony Drops suitable for both men and women?

Official marketing describes Sugar Harmony Drops as containing premium vitamins for women and men. Published research on individual ingredients has included both male and female study participants. Adults considering this product should consult a healthcare provider, particularly if taking medications or managing existing health conditions.

Where is Sugar Harmony Drops sold?

The official product website is getsugarharmony.com. Purchases are processed through ClickBank. The product also appears on marketplace platforms including Amazon under the Syvor brand name. The company advises verifying product authenticity when purchasing through any channel.

Additional Consumer Research

Independent research across multiple consumer publications and peer-reviewed sources may provide broader perspective on metabolic wellness supplements, liquid supplement bioavailability, and the specific ingredients referenced in Sugar Harmony Drops. Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also wish to review the FDA’s general guidance on dietary supplement labeling and claims.

Summary of Key Considerations

Sugar Harmony Drops is a liquid dietary supplement positioned in the wellness support category with ingredient references that include Gymnema Sylvestre, Chromium Picolinate, Cinnamon, Bitter Melon, and additional botanicals. The product references ingredients with published research at the individual compound level. However, individual ingredient dosages per serving don’t appear to be publicly disclosed, and publicly available sources do not indicate a published clinical study evaluating the finished product as formulated.

The company provides a 60-day refund guarantee processed through ClickBank, with multi-bottle pricing starting at $49 per bottle for the 6-bottle package. The 6-bottle fulfillment structure includes an additional QR code activation step described in the Terms of Service. Marketing disclaimers on the official website note that the product has not been evaluated by the FDA and that individual results may vary.

For consumers who want to review the full product details directly, complete product information, current pricing, and published terms are available by viewing the current Sugar Harmony Drops offer (official Sugar Harmony Drops page).

Contact Information

Company: SugarHarmony Research

Return Address: 285 Northeast Ave, Tallmadge, OH 44278

Email: support@getsugarharmony.com

Website: getsugarharmony.com

Payment Processor: Click Sales Inc., 1444 S. Entertainment Ave., Suite 410, Boise, ID 83709

Self-Service Billing Support: https://www.clkbank.com/

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

Supplement and Health Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the manufacturer regarding this product have not been evaluated by the Food and Drug Administration. Individual results vary based on numerous factors including age, baseline health, dietary habits, activity level, and consistency of use. Health and wellness concerns should be discussed with a qualified healthcare provider who is familiar with the individual’s personal medical history.

Results, Pricing, and Product Variability: All pricing, bonus offers, shipping terms, and refund policies referenced in this article are based on information published on the official product website at the time of writing and may change without notice. Consumers should verify current terms through the official website or the authorized payment processor before completing any purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. Click Sales Inc. (ClickBank) serves as the authorized payment processor for this product. ClickBank’s role as retailer does not constitute an endorsement, approval, or review of this product or any claim, statement, or opinion used in its promotion. The publisher of this article is not responsible for typographical errors, manufacturer changes to the product after publication, or individual consumer outcomes.

CONTACT: Email: support@getsugarharmony.com

Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment

Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment




Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment

An informational consumer overview of Zealthy’s prescription hydroquinone program, including compounded medication status, FDA context, telehealth dermatology consultation details, subscription and refund terms, side effect considerations, and key verification steps for 2026

New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview for consumer education. It does not constitute medical, dermatological, or healthcare advice. Prescription treatment requires evaluation by a licensed clinician, and a prescription is not guaranteed. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

Consumer search interest in prescription hydroquinone online and telehealth dermatology consultations has grown as regulatory changes continue to reshape how hydroquinone products reach patients in the United States. For many consumers, the shift from over-the-counter availability to prescription-based access has raised practical questions about cost, process, and what to expect from an online skincare consultation.

Consumers researching Zealthy hydroquinone in 2026 tend to have the same questions: Is a prescription required? Is the product compounded or commercially manufactured? What does the dermatology visit actually involve? How much does it cost? And what should someone verify before committing to a treatment plan?

Current product details, pricing, and terms can be confirmed by viewing the current Zealthy hydroquinone offer (official Zealthy hydroquinone page).

This overview addresses each of those questions using publicly available information from the Zealthy website, the company’s published terms of use, and independent regulatory context.

Zealthy Hydroquinone 2026 Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment

What Zealthy Hydroquinone Is

According to the Zealthy website, the company describes access to prescription-strength hydroquinone that is personalized to each patient’s skin through an online dermatology consultation. The service is presented as a telehealth-based skincare program that connects consumers with licensed dermatology providers who evaluate skin concerns and, if medically appropriate, prescribe a customized hydroquinone treatment plan.

It’s worth understanding how the service is structured. Per the company’s published terms of use, Zealthy is operated by FitRX, LLC and described as a technology platform that facilitates connections between patients and independent healthcare providers. Medical services, including prescriptions and treatment decisions, are stated to be provided solely by independent healthcare providers associated with affiliated medical groups. Zealthy itself doesn’t prescribe medications or make treatment decisions — the providers do.

The hydroquinone described on the Zealthy page is presented as a compounded prescription product prepared by a partner pharmacy based on an individual prescription. Compounded medications are legally dispensed with a valid prescription but are not reviewed by the FDA as finished, commercially manufactured drug products. That’s an important distinction for consumers to understand before starting treatment.

In plain terms, compounding refers to a pharmacy preparing a medication for an identified individual patient based on a prescription. The FDA has noted that compounded drugs are not FDA-approved and have not been reviewed for safety, effectiveness, or quality in the same manner as commercially manufactured drug products. This does not make compounded medications illegal — it means they follow a different regulatory pathway, and the quality of the final product depends on the practices of the individual compounding pharmacy.

Hydroquinone Regulatory Context in 2026

Consumer interest in prescription hydroquinone access increased after U.S. reforms to the nonprescription drug framework. Following the 2020 CARES Act changes, FDA communications have emphasized that OTC skin-lightening drug products containing hydroquinone are generally treated as unapproved drugs when marketed without FDA approval, which has contributed to a shift toward prescription-based pathways.

In the U.S., hydroquinone is commonly encountered through prescription-based dermatology care, including clinician-directed compounding. Consumers may see hydroquinone offered either as a commercially manufactured prescription drug product (where applicable) or as a patient-specific compounded prescription prepared by a licensed pharmacy. The Zealthy page describes its offering as compounded, meaning it’s dispensed pursuant to an individual prescription and is not FDA-reviewed as a finished product.

Many patient-specific compounded prescriptions in the U.S. are prepared through state-licensed compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Patients can request the dispensing pharmacy’s name and licensing information as part of their due diligence before beginning any compounded prescription.

How the Zealthy Online Dermatology Process Is Described

The Zealthy website describes a straightforward telehealth process for its skincare consultation. Consumers create an account and answer health-related questions about their skin concerns — a step the company says takes about five minutes. A licensed dermatology provider then reviews the submitted information and, in some cases, uploaded photographs. If the provider determines that prescription treatment is medically appropriate, a personalized treatment plan is created and the prescribed medication is shipped to the consumer.

Zealthy’s published terms emphasize that a prescription is not guaranteed. The provider will only issue a prescription if they deem it medically relevant and appropriate, which is consistent with standard telehealth practice and applicable medical regulations. This isn’t a checkout process — it’s a clinical evaluation.

What the Zealthy Hydroquinone Package Includes

The Zealthy product page describes the hydroquinone treatment package as including a three-month supply of compounded hydroquinone formula, presented as prescription-strength and customized for the individual patient’s skin type. The package also includes an online dermatology visit with a licensed provider and shipping on the prescribed medication.

Additional medications that may be part of a broader Zealthy skincare program, according to the company’s published treatment options, include tretinoin formulas, clindamycin with benzoyl peroxide, azelaic acid, tazarotene, and adapalene for topical treatment, as well as oral options such as doxycycline, cephalexin, spironolactone, and minocycline. Which medications are prescribed depends entirely on the treating provider’s clinical assessment.

Zealthy Hydroquinone Pricing and Consultation Cost

The Zealthy page lists an online dermatology consultation price of $20 at the time of this review. Pricing and promotional terms can change, and consumers should confirm current pricing directly on the official website before beginning the consultation process.

According to the published subscription and refund policy, the consultation fee and any membership charges are separate from medication costs. Prescription treatments are priced per medication and delivered monthly, per publicly available information. The exact cost of the compounded hydroquinone formula isn’t prominently listed on the landing page and may depend on the specific formulation prescribed by the provider.

Consumers can confirm current pricing and availability by viewing the current Zealthy hydroquinone offer (official Zealthy hydroquinone page), as pricing may change at any time.

Insurance coverage for compounded medications varies by plan. The company’s published terms note that services purchased through the platform may not be billed to or covered by health insurance, though consumers may have the option to transfer prescriptions to an outside pharmacy where insurance coverage might apply.

Zealthy Subscription, Cancellation, and Refund Terms

Zealthy’s published Subscription, Cancellation, and Refund Policy contains several terms that are worth reviewing before beginning treatment. Here’s what the published policy covers, based on information available at the time of this review.

For prescription medications, the company states that all sales are final. Once a prescription has been filled by a partner pharmacy, refunds are not available and returns are not accepted. The company states this policy exists to protect medication integrity and comply with applicable laws.

For consultation fees and membership charges, the published policy states these are also non-refundable. Membership can be cancelled at any time through the patient account. Upon cancellation, consumers may continue using services until the end of the current billing cycle but are not eligible for prorated refunds.

Consumers can review the current policy directly on the company’s website before enrolling to confirm that these terms have not changed since this article was published.

Potential Side Effects of Prescription Hydroquinone

Only a licensed clinician can determine whether hydroquinone is appropriate for a specific patient. Consumers should discuss potential risks and side effects before use, including the following concerns commonly reported in dermatological literature.

The Zealthy consent documentation lists several potential side effects associated with topical skincare treatments prescribed through the platform, including skin irritation, increased sun sensitivity, initial acne flare-up, burning or stinging sensation, contact dermatitis, hyperpigmentation or hypopigmentation, allergic reactions, and specifically for hydroquinone, ochronosis — a condition where prolonged use may cause blue-black pigmentation to develop on the skin.

Some clinical literature associates ochronosis risk with prolonged or unsupervised use, which is one reason prescription hydroquinone typically involves clinician monitoring and defined treatment periods. Patients should follow individualized guidance from their prescriber regarding how the medication should be used, the intended course of use as determined by the prescriber, and sun-exposure management.

Zealthy Hydroquinone and Skin Improvement Expectations

Consumer searches frequently include terms such as Zealthy hydroquinone results, does Zealthy hydroquinone work, and how long does hydroquinone take. Here’s how hydroquinone is commonly described in dermatology references, and how expectations are typically framed in clinical discussions.

The mechanism behind hydroquinone involves inhibiting the enzyme tyrosinase, which plays a role in melanin production. By reducing melanin synthesis in treated areas, hydroquinone can gradually lighten hyperpigmented skin. This mechanism is well documented in dermatology literature and forms the basis for its use in treating conditions such as melasma, post-inflammatory hyperpigmentation, and sun-induced dark spots.

That said, individual results vary significantly. Timelines depend on diagnosis, formulation, skin type, sun exposure, and adherence to clinician guidance. No outcome or timeline is guaranteed. Some clinical discussions of hydroquinone use describe changes emerging over weeks with consistent use, but there’s no universal standard for how quickly any individual patient will see improvement.

The Zealthy website includes testimonials describing individual experiences. Testimonials are self-reported statements published by the company, are not independently verified clinical evidence, and should not be interpreted as typical or guaranteed outcomes.

Eligibility, Exclusions, and When In-Person Care May Be Needed

Telehealth may not be appropriate for all skin concerns, and it’s worth considering whether an online consultation is the right starting point for a given situation before beginning the process.

Consumers should seek in-person care for rapidly changing lesions, symptoms requiring close-up examination with specialized instruments, or any condition a clinician believes needs physical evaluation. Hydroquinone treatment is intended for specific types of hyperpigmentation, and a proper diagnosis matters — treating the wrong condition with the wrong product can be counterproductive.

The Zealthy process includes a provider evaluation step, but the scope of any telehealth assessment has inherent limitations compared to an in-person dermatology visit. Consumers with complex skin histories or conditions beyond straightforward hyperpigmentation may benefit from seeing a dermatologist in person before pursuing telehealth treatment.

Compounded Prescription Labeling: What Consumers Can Request

Before starting any compounded hydroquinone treatment, patients can request the prescription label details from the dispensing pharmacy. This includes the active ingredient concentration, base formulation, directions from the prescriber, beyond-use date, and pharmacy contact information.

Having this information helps consumers understand exactly what’s being dispensed and provides a reference point for follow-up conversations with the prescribing provider about treatment progress or any adjustments.

How to Evaluate an Online Prescription Skincare Service

Consumers evaluating any telehealth skincare platform, including Zealthy, benefit from verifying several factors before committing to treatment.

Confirming the clinician’s state license and the medical group name is a straightforward starting point. Requesting the name and licensing information of the dispensing pharmacy is another reasonable step. Total cost clarity matters too — this means understanding the consultation fee, medication costs, any recurring membership charges, and shipping before paying. Consumers should also understand the refill schedule and how follow-up appointments are handled. Reviewing refund and cancellation terms before enrolling is always worth the few minutes it takes.

Consumers considering compounded hydroquinone may also find it helpful to ask the prescribing clinician specific questions: what concentration is being prescribed, whether additional active ingredients are included in the formula, which pharmacy will dispense the medication, and what follow-up schedule is recommended for monitoring tolerance and treatment response.

Telehealth Skincare Services in 2026: Category Context

The telehealth dermatology market has expanded significantly since 2020, driven in part by the shift in hydroquinone availability from over-the-counter to prescription-based access. Multiple platforms now offer online consultations for prescription skincare, each with different pricing structures, provider networks, and medication sourcing approaches.

When comparing services, consumers should consider whether the platform uses compounded or commercially manufactured medications, the qualifications of prescribing providers, total cost including consultation and medication, subscription and cancellation terms, and whether ongoing clinical monitoring is provided throughout the treatment period.

Sun Protection Context During Hydroquinone Treatment

Clinicians commonly emphasize sun-exposure management during treatment for hyperpigmentation because UV exposure may worsen discoloration and counteract treatment effects. Patients should follow individualized sun protection guidance from their prescriber based on their skin type, location, and daily exposure patterns.

Who Might Consider Zealthy for Prescription Hydroquinone

Based on the company’s published service description, Zealthy’s hydroquinone program appears designed for consumers seeking prescription-strength hyperpigmentation treatment who prefer a fully online consultation process. The service may be particularly relevant for individuals who face barriers to in-person dermatology visits, including long wait times, geographic limitations, or scheduling constraints that make traditional clinic appointments difficult to maintain.

That said, telehealth dermatology isn’t appropriate for every skin condition, and consumers should confirm that the subscription-based pricing model and stated refund terms work for their situation before beginning the consultation process.

Consumer Questions About Zealthy Hydroquinone

Is Zealthy hydroquinone FDA-approved?

The hydroquinone prescribed through Zealthy is compounded, meaning it’s prepared by a partner pharmacy based on an individual prescription. It is not an FDA-approved finished product. These types of compounded preparations are legally prescribed and dispensed but have not undergone the same review process as commercially manufactured pharmaceutical products.

Do I need a prescription to get hydroquinone through Zealthy?

Yes. In the United States, prescription-strength hydroquinone requires a valid prescription from a licensed healthcare provider. The Zealthy platform facilitates an online consultation where a provider evaluates whether a hydroquinone prescription is medically appropriate. A prescription is not guaranteed.

How much does the Zealthy online dermatology visit cost?

Zealthy lists the online dermatology consultation at $20 at the time of this review. Additional medication costs are separate from the consultation fee. Consumers should verify current pricing on the official website, as terms may change.

What is the difference between compounded hydroquinone and commercially manufactured hydroquinone?

Commercially manufactured prescription hydroquinone products go through the FDA’s new drug application approval process. Compounded hydroquinone is prepared at concentrations determined by the prescribing provider, customized for individual patients, and dispensed through licensed compounding pharmacies. Compounded products are legal with a valid prescription but are not FDA-reviewed as finished products.

How long does hydroquinone take to show results?

Timelines vary. Some clinical discussions describe changes emerging over weeks with consistent use, but individual response depends on diagnosis, formulation, skin type, sun exposure, and adherence to clinician guidance. No outcome or timeline is guaranteed. The Zealthy hydroquinone package is described as a three-month supply, which aligns with commonly discussed treatment durations in dermatological literature.

What are the potential side effects of hydroquinone?

Potential side effects include skin irritation, increased sun sensitivity, burning or stinging, contact dermatitis, and changes in skin pigmentation. With prolonged unsupervised use, hydroquinone has been associated with ochronosis. Clinician monitoring and defined treatment periods are recommended to minimize risk. Patients should discuss potential side effects with their prescribing provider before starting treatment.

Can I cancel my Zealthy subscription?

Per the published policy, consumers can cancel at any time through their account. However, prescription medication purchases are described as final and non-refundable once filled by the partner pharmacy. Consultation fees and membership charges are also stated as non-refundable. Reviewing the complete policy on the Zealthy website before enrolling is recommended.

Is Zealthy a healthcare provider?

As stated in the published terms of use, Zealthy (operated by FitRX, LLC) is a technology platform, not a healthcare provider. Medical services are provided by independent healthcare providers associated with affiliated medical groups. Zealthy facilitates the connection between patients and providers but does not itself prescribe medications or make treatment decisions.

Does insurance cover Zealthy hydroquinone?

Coverage varies by plan. The platform’s published terms indicate that services purchased through Zealthy may not be billed to or covered by health insurance. However, consumers may be able to transfer prescriptions to an outside pharmacy where insurance coverage could apply. Contacting an insurance provider directly is the most reliable way to determine coverage eligibility for compounded hydroquinone.

Can men use Zealthy hydroquinone?

Hydroquinone is used to treat hyperpigmentation in both men and women. The treating provider will evaluate whether the medication is appropriate based on the individual’s skin concerns and medical history, regardless of gender.

Is hydroquinone safe for all skin types?

Hydroquinone has been used across a range of skin types, but individual responses vary. Patients with darker skin tones should discuss potential risks, including paradoxical hyperpigmentation, with their provider before beginning treatment. Clinician supervision is particularly important for patients who have previously experienced adverse reactions to topical skin treatments.

What should I request from the compounding pharmacy?

Patients can request the prescription label details including active ingredient concentration, base formulation, directions from the prescriber, beyond-use date, and pharmacy contact information. This information helps consumers understand what’s being dispensed and provides a reference point for follow-up conversations with the prescribing provider.

Additional Consumer Research

Additional independent research across multiple consumer publications and dermatological resources may provide broader perspective on this product category. Evaluating multiple sources is recommended before making any purchasing decision.

Consumers researching Zealthy’s broader telehealth platform may also find it useful to review an independent overview of Zealthy’s telehealth ED treatment options, compounded medication pricing, and consumer verification considerations, which covers similar themes of provider licensing, compounding transparency, and subscription terms across a different service category on the same platform.

Summary of Key Considerations

Zealthy hydroquinone describes prescription access to compounded hydroquinone through an online dermatology consultation process. The product is not an FDA-approved finished product but is legally prescribed through the platform’s network of independent licensed providers. The service is described as relevant for consumers researching treatment options for dark spots, melasma, hyperpigmentation, and uneven skin tone who prefer the convenience of a virtual consultation.

Before beginning treatment, consumers should verify current pricing, review subscription and refund terms in full, confirm clinician licensing, request compounding pharmacy details, and discuss potential side effects with their assigned provider. Complete product details, current pricing, and published terms are available by viewing the current Zealthy hydroquinone offer (official Zealthy hydroquinone page).

Contact Information

FitRX, LLC dba Zealthy

30 Irving Pl, Floor 7

New York, NY 10003

Phone: (877) 870-0323

Email: support@getzealthy.com

Website: https://try.getzealthy.com/hydroquinone/

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview intended for general consumer education purposes. It does not constitute medical, dermatological, healthcare, or professional advice of any kind. The information presented has not been independently audited or verified unless specifically noted. All product and service descriptions are based on publicly available information as presented by the company and may change without notice. Consumers should consult with a qualified healthcare provider before beginning any prescription skincare treatment.

Compounded Medication Notice: The hydroquinone product described in this article is a compounded medication, not an FDA-approved finished product. Compounded medications are legally prescribed and dispensed through licensed pharmacies but have not undergone the FDA’s new drug application approval process. The safety, effectiveness, and quality of compounded preparations depend on the practices of the individual compounding pharmacy. Consumers should discuss the differences between compounded and commercially manufactured medications with their healthcare provider.

Results, Pricing, and Service Variability: Individual treatment results vary based on skin type, condition severity, adherence to treatment, and other factors. No specific outcomes are guaranteed. Pricing, service terms, subscription structures, provider availability, and refund policies may change without notice. All current terms should be verified directly through the Zealthy website and the assigned provider before making purchasing decisions.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented in this review. All opinions and descriptions are based on publicly available details and are intended to help readers make informed decisions.

CONTACT: Phone: (877) 870-0323
Email: support@getzealthy.com

Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting

Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting




Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting

Informational consumer guide examines Zealthy’s online ED treatment model, sublingual Hardies formulations, provider evaluation process, subscription structure, and compounded medication disclosures for men evaluating prescription erectile dysfunction options in 2026.

New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, healthcare, or treatment advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision. Erectile dysfunction medications are prescription products that require evaluation by a licensed healthcare provider. Individual results vary, and not all applicants will qualify for treatment.

More men are searching for terms like Zealthy ED, Zealthy Hardies, and telehealth erectile dysfunction treatment as online prescription platforms continue to reshape how erectile dysfunction is treated in the United States. The questions driving those searches tend to follow a predictable pattern: How can consumers verify the platform’s business and clinical setup? What medications are available? How does pricing actually work when you factor in membership fees? And what does it mean when a product is compounded rather than FDA-approved?

This guide was built to answer those questions directly. It covers how Zealthy operates, what the medication options look like, how compounded prescriptions differ from FDA-approved finished products, what the real cost structure is when you add everything up, and what any man should think through before starting a prescription ED treatment online.

Current product details, pricing, and terms can be confirmed by viewing the current Zealthy ED offer (official Zealthy ED page).

A note before reading further: Erectile dysfunction can be a signal of underlying health conditions including cardiovascular disease, diabetes, and hormonal imbalances. Any man experiencing persistent erectile difficulties should have a conversation with a qualified healthcare provider for a thorough evaluation before pursuing any treatment — whether through an online platform or a traditional office visit. This guide provides informational context, not medical advice.

Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations) Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting

What Zealthy Is and How the ED Platform Works

Zealthy is a telehealth technology platform headquartered in New York, NY, operating under the legal entity FitRX, LLC. The company launched in 2023 and facilitates virtual access to licensed healthcare providers across several health categories, including primary care, weight management, mental health, skincare, hair loss, and erectile dysfunction treatment.

One of the first things to understand about Zealthy is what it is and what it is not. The company’s published Terms of Use make this distinction clear: Zealthy is a technology facilitator, not a healthcare provider. It does not prescribe medications or make treatment decisions. Those responsibilities fall to independent healthcare providers affiliated with Bruno Health, P.A., Outlast Health, and associated medical groups. These clinicians are not Zealthy employees — they exercise independent clinical judgment when evaluating patients and deciding whether treatment is appropriate.

For ED services specifically, the process starts with an online medical assessment that Zealthy describes as taking roughly ten minutes. The questionnaire collects information about medical history, current medications, and symptoms. A licensed provider then reviews the submitted information and determines whether a prescription is clinically warranted. Not all applicants will qualify, and approval is never guaranteed.

If a provider determines that treatment is appropriate, medications are dispensed through Zealthy’s partner pharmacy network and shipped directly to the patient in discreet packaging. The company emphasizes that no in-person appointment or live video consultation is required for the initial evaluation — the provider reviews everything asynchronously. Patients have access to ongoing messaging with their care team for follow-up questions and dosage discussions, though messaging access does not replace emergency care, and response times can vary based on provider availability.

Zealthy ED Medication Options

Zealthy’s ED services include access to several medication formats, organized around how and when the medication is taken. The descriptions below reflect information published on Zealthy’s official product pages as of February 2026 and should be verified directly before making any decisions.

Standard oral medications include sildenafil and tadalafil, both FDA-approved generic PDE-5 inhibitors prescribed for erectile dysfunction. These are FDA-approved active ingredients used in prescription ED medications when prescribed by a licensed provider. Sildenafil is typically taken before sexual activity. Tadalafil comes in both as-needed and daily-use formulations. Both require a prescription, and individual response varies.

Zealthy Hardies are the platform’s proprietary sublingual formulation — and the product that generates the most consumer questions. Hardies are compounded prescription medications that dissolve under the tongue rather than being swallowed as traditional pills. The sublingual delivery method is described by the company as allowing active ingredients to absorb directly into the bloodstream, bypassing the digestive system.

Company materials describe certain sublingual formulations as beginning to take effect in approximately 15 minutes for some patients, though onset time can vary based on individual health factors, dosage, and provider direction. The tablets are described as taking about 10 minutes to dissolve completely. These timeframes reflect the company’s published product descriptions and should be discussed with a prescribing provider.

Three Hardies formulations are currently listed on Zealthy’s product pages:

Sildenafil plus Tadalafil Hardies combine both FDA-approved PDE-5 inhibitors into a single sublingual dose. Dosage options listed by the company include sildenafil 200 mg with tadalafil 40 mg, as well as lower-strength combinations. Published product information references effects lasting up to 36 hours, though duration varies by individual.

Sildenafil plus Oxytocin Hardies pair sildenafil 110 mg with oxytocin 110 IU. Oxytocin is a hormone that occurs naturally in the body and is included in certain compounded formulations. Patients should discuss whether any compounded combination is appropriate for their situation with a licensed prescriber.

Tadalafil plus Oxytocin Hardies combine tadalafil 25 mg with oxytocin 125 IU. Zealthy’s product pages position this formulation as part of the longer-lasting sublingual option. As with all Hardies products, this is a compounded medication that requires a prescription, and appropriateness should be evaluated by a provider.

Zealthy’s published Hardies safety disclosure also states that Hardies may contain sildenafil, tadalafil, oxytocin, and vardenafil depending on the formulation. Consumers should confirm the exact ingredients and dosage on the product page and with the prescribing provider before use.

What “Compounded” Means and Why It Matters

This may be the most important section of this entire guide for anyone researching Zealthy Hardies. The distinction between a compounded medication and an FDA-approved finished product has real implications that every prospective patient should understand before making a purchasing decision.

Zealthy Hardies are compounded prescription medications. Compounded drugs are prepared by licensed compounding pharmacies and are permitted under federal law. However, as Zealthy’s own published safety information states directly: compounded drugs are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review.

What does that mean in plain language? Sildenafil and tadalafil are FDA-approved active ingredients used in prescription ED products. However, Zealthy’s Hardies are compounded prescriptions, and Zealthy’s published disclosure states that compounded drugs are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review. The specific Hardies combination products — the particular ingredient pairings, the sublingual delivery format, and the dosage configurations — have not been reviewed by the FDA as finished products. The compounding pharmacy prepares the medication according to the prescribing provider’s specifications, but the finished product itself has not been reviewed by the FDA.

This distinction does not automatically mean a compounded product is unsafe. What it does mean is that consumers should understand the regulatory framework and discuss it with a qualified healthcare provider. Men who want only FDA-reviewed finished products may prefer standard generic sildenafil or tadalafil tablets. Men who are open to compounded formulations after discussing them with a prescriber may find the Hardies sublingual format worth exploring. Either way, understanding the distinction puts the consumer in a stronger position to make an informed decision.

Zealthy ED Pricing: What It Actually Costs

Pricing is often the first thing men research, and it is also the area where incomplete information can create the most confusion. Zealthy’s ED pricing involves two components that should be evaluated together: medication costs and the recurring membership fee. The following information is stated as presented on Zealthy’s official product pages as of February 2026. Pricing, promotions, and plan terms can change, so verifying current details on the official page before enrolling is recommended.

Hardies pricing references on the company’s website vary slightly by formulation and product page. One product page lists Hardies at approximately $9 per dose on certain subscription plans. A separate page for the Sildenafil plus Tadalafil 200 mg/40 mg formulation references $11 per Hardie. Subscription plans are offered in one-month, three-month, and five-month supply durations, with plan sizes ranging from 4 to 30 Hardies per month.

Standard generic oral medications, including sildenafil and tadalafil in pill form, are listed at lower per-dose price points. Company advertising references tadalafil at per-pill rates that can be lower depending on plan terms and quantity selected.

The membership fee is a separate recurring charge. Zealthy’s published Subscription, Cancellation and Refund Policy describes a membership fee that covers access to provider consultations, messaging with care teams, and platform services. This fee is billed automatically on a recurring basis and is charged in addition to the cost of medications. Consumers calculating total monthly cost should add the membership fee to their medication expense to arrive at the true out-of-pocket number.

The company’s advertising references an introductory promotion on the first order, subject to eligibility and change. Promotional terms and expiration should be verified directly.

Consumers can confirm current pricing and availability by viewing the current Zealthy ED offer (official Zealthy ED page), as pricing may change at any time.

Cancellation, Refunds, and Subscription Terms

Before committing to any subscription, taking the time to review cancellation and refund terms is one of the most practical steps a consumer can take. Zealthy’s published Subscription, Cancellation and Refund Policy outlines several provisions worth understanding upfront.

Prescription medications: all sales are final. The published policy states that Zealthy cannot issue refunds or accept returns of prescription products for any reason. Once a prescription has been issued and filled by the partner pharmacy, it cannot be returned or refunded. The company states this is to protect medication integrity and comply with applicable laws.

Consultation fees and membership charges are non-refundable. Charges associated with provider visits and the recurring membership are stated as non-refundable in the published policy.

Cancellation is managed through the patient account. Zealthy’s cancellation terms state that members can cancel at any time by logging into their account and navigating to the membership management section. If a subscription is cancelled before the current term expires, the member can continue using services through the end of the paid period but will not receive a prorated refund for the remaining time.

It is worth reviewing the complete policy on the official website before subscribing. Billing questions can be directed to support@getzealthy.com.

Safety Information and Contraindications

All erectile dysfunction medications — whether FDA-approved finished products or compounded formulations — carry safety considerations that should be part of any treatment decision. The following safety information is sourced from Zealthy’s published product disclosures for the Hardies line.

Hardies should not be taken more than once in any 24-hour period, or within 24 hours of taking any other ED medications or PDE-5 inhibitors.

Do not take Hardies while using nitrates or soluble guanylate cyclase stimulators. This combination can cause a sudden and dangerous drop in blood pressure.

Hardies should not be used by anyone who is not healthy enough for sexual activity. Sexual activity places cardiovascular demands on the body, and men with certain heart conditions should discuss this with their physician before using any ED medication.

Seek emergency medical care immediately if an erection lasts longer than 4 hours, if sudden loss of vision occurs in one or both eyes, or if sudden hearing loss occurs.

Exercise caution when taking alpha-blockers, blood pressure medications, or when consuming more than 5 units of alcohol.

Common side effects listed by the company include headache, flushing, indigestion, abnormal vision, back pain, muscle pain, nasal congestion, dizziness, nausea, pain in limbs, and rash. This list may not cover all possible side effects. A complete medical history should be discussed with the prescribing provider before beginning treatment.

Platform, Providers, and Pharmacy: Understanding Who Does What

With any telehealth service, understanding which entity handles which part of the experience helps set realistic expectations and ensures questions get directed to the right place. Zealthy’s model involves three distinct entities.

Zealthy (FitRX, LLC) runs the technology platform. The published Terms of Use state that Zealthy does not provide medical care, prescribe medications, or act as a healthcare provider. It builds and maintains the digital infrastructure that connects patients with clinicians and pharmacies.

Bruno Health, P.A., Outlast Health, and affiliated medical groups supply the independent healthcare providers who evaluate patients, make treatment decisions, and write prescriptions when clinically appropriate. These providers are not Zealthy employees.

Partner pharmacies fill and ship prescriptions. For compounded products like Hardies, the partner pharmacy handles the actual compounding — preparing the specific combination of ingredients according to the prescribing provider’s directions.

In practice, this means medical questions should go to the assigned provider through the platform messaging system. Billing and subscription issues are handled by Zealthy’s support team. Medication quality or fulfillment concerns would involve the pharmacy partner. Messaging access does not replace emergency care, and response times vary based on provider availability.

Evaluating Zealthy Against the Broader Telehealth ED Market

The telehealth ED treatment space has grown considerably, and consumers have more options now than at any previous point. Without endorsing or naming specific alternatives, understanding the general differentiators across the market helps frame what Zealthy offers and where a consumer might want to compare further.

Medication format: Most telehealth ED platforms offer standard oral tablets — sildenafil or tadalafil in pill form. A smaller number offer alternative delivery formats such as sublingual tablets, chewables, or multi-ingredient combinations. Zealthy’s Hardies fall into this alternative-format category with sublingual delivery and combination ingredients.

Pricing structure: Some platforms charge per-dose with no membership. Others, including Zealthy, use a subscription model with recurring membership charges plus medication costs. When comparing across platforms, calculating total cost — membership plus medication plus any additional fees — produces the clearest picture.

Provider interaction: The range runs from fully asynchronous text-based evaluations to required video consultations. Zealthy’s model is primarily asynchronous, meaning the initial evaluation does not require a live video or phone appointment. Some men prefer this privacy level; others may feel more comfortable with a live conversation before starting prescription medication.

Compounded versus non-compounded: Not every telehealth ED platform offers compounded medications. Some provide only FDA-approved generics in their standard approved forms. Consumers should confirm which type of medication they would be receiving and understand the regulatory distinction outlined earlier in this guide.

Underlying Health Considerations: Why ED Evaluation Matters Beyond Medication

One of the most underappreciated aspects of erectile dysfunction is that it can sometimes be associated with underlying health issues, including cardiovascular or metabolic factors. For that reason, any man experiencing persistent erectile difficulties should view it not just as a standalone concern to be treated, but as a prompt to have a broader health conversation with a qualified clinician. A thorough evaluation may uncover contributing factors that medication alone would not address. Telehealth platforms can provide access to prescription treatment, but they are not a substitute for comprehensive primary care evaluation — a point Zealthy itself acknowledges in its published Terms of Use.

Who Might Evaluate Zealthy’s ED Services

Based on the platform’s described service model, several types of consumers may find Zealthy’s ED offerings worth researching further. This section describes general consumer profiles, not treatment recommendations. Only a licensed healthcare provider can determine whether a specific ED treatment is appropriate for an individual patient.

Men who value the privacy of an asynchronous online evaluation and prefer not to schedule an in-person visit may find the telehealth workflow convenient. Zealthy describes the initial assessment as not requiring a video consultation.

Consumers interested in sublingual or alternative-format medications may want to research the Hardies product line, keeping in mind the compounding disclosures covered earlier and discussing any compounded formulation with a licensed provider before use.

Men currently managing ED with standard sildenafil or tadalafil who are curious about different delivery methods should discuss any changes to their existing treatment plan with a healthcare provider before switching or adding medications.

Individuals comparing total treatment costs across platforms should calculate membership fees plus medication costs together to arrive at an accurate monthly number. Comparing that total against retail pharmacy pricing for standard generics, as well as against other telehealth platforms, gives the most complete cost picture.

Consumer Questions About Zealthy ED

How can consumers verify whether Zealthy is a legitimate telehealth platform?

When evaluating any telehealth platform, consumers can verify the business entity and support contacts listed in the Terms of Use, check the prescribing provider’s license through their state medical board, and review the pharmacy disclosures and compounding language on the medication information pages. Zealthy operates under FitRX, LLC, headquartered at 30 Irving Place, Floor 7, New York, NY 10003, with a published phone number of (877) 870-0323 and email support at support@getzealthy.com.

Are Zealthy Hardies FDA-approved?

No. The Hardies product line consists of compounded prescription medications. Zealthy’s own published safety disclosures state that compounded drugs are permitted under federal law but are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review. The individual active ingredients — sildenafil and tadalafil — hold separate FDA approvals for treating erectile dysfunction. The specific Hardies combination products and sublingual format have not received FDA approval as finished products.

How does onset time for Hardies compare to standard ED pills according to the company?

Zealthy’s product pages list the Sildenafil plus Tadalafil and Sildenafil plus Oxytocin sublingual formulations as beginning to take effect in about 15 minutes on average. The Tadalafil plus Oxytocin formulation is listed at approximately one hour. Onset time varies by person and product, and patients should confirm expectations with the prescribing provider.

What is the total monthly cost of Zealthy ED treatment?

Total monthly cost depends on medication type, dosage, quantity, and subscription duration — plus the recurring membership fee. Company materials reference Hardies starting at approximately $9 per dose on certain subscription plans, with some formulations around $11 per dose. Standard oral medications are listed at lower per-dose rates. Adding the membership fee to the medication cost gives the full monthly picture. Pricing and promotions can change, so verifying current terms on the official page is recommended.

What are the cancellation and refund terms?

Zealthy’s refund terms indicate that prescription medication purchases are final sale. Membership charges are described as non-refundable for the current billing period. Members can cancel at any time through their account settings. Complete terms should be reviewed on the official website before subscribing.

Does Zealthy accept health insurance for ED medications?

Zealthy’s Terms of Use indicate that medications filled through the platform are not billed to health insurance plans. Patients may request to have a prescription transferred to an outside pharmacy, which could allow insurance coverage depending on individual plan terms. Transfer requests can be directed to support@getzealthy.com.

What is the difference between compounded and FDA-approved generic ED medications?

FDA-approved generic medications like sildenafil and tadalafil tablets have completed the full FDA review process for safety, effectiveness, and manufacturing quality. Compounded medications such as Hardies are prepared by licensed pharmacies and may combine multiple ingredients or use alternative delivery methods, but the finished product has not undergone that same review. Both types require a prescription from a licensed provider. Understanding this distinction is one of the most important steps in evaluating any compounded medication option.

Is a video appointment required to get started?

Zealthy’s published materials describe the initial evaluation as an online questionnaire reviewed asynchronously by a licensed provider — no live video or phone appointment is required. Messaging-based follow-up with the care team is available after enrollment. Messaging access does not replace emergency care, and response times vary.

What happens if a provider decides treatment is not appropriate?

Zealthy’s Terms of Use state that users are not entitled or guaranteed to receive a prescription. Providers only issue prescriptions when they determine treatment is medically relevant and appropriate. If a provider determines that medication is not suitable based on the information submitted, following up with a primary care physician or urologist for further evaluation is the recommended next step.

What are the potential side effects of ED medications?

All PDE-5 inhibitors, including sildenafil and tadalafil, carry potential side effects. Common side effects listed by the company for Hardies include headache, flushing, indigestion, abnormal vision, back pain, muscle pain, nasal congestion, dizziness, nausea, and rash. Serious but rare risks include priapism (erection lasting more than 4 hours), sudden vision or hearing changes, and dangerous blood pressure drops when combined with nitrates. A complete discussion of risks and medical history should take place with the prescribing provider before starting treatment.

What active ingredients are in Zealthy Hardies?

Zealthy’s published safety disclosures list the ingredients as combinations of sildenafil, tadalafil, oxytocin, and vardenafil depending on the formulation. The three currently listed products are Sildenafil plus Tadalafil, Sildenafil plus Oxytocin, and Tadalafil plus Oxytocin. Specific ingredients and dosages for any selected product should be confirmed with the prescribing provider.

How are medications shipped?

Zealthy’s published materials describe medications as being shipped to the patient’s home in discreet, unmarked packaging. The platform notes that it is not responsible for orders after shipment from partner pharmacies, and any lost or stolen package claims should be directed to the delivery carrier.

Additional Consumer Research

Consumers evaluating any telehealth ED platform are encouraged to research across multiple independent sources before making a decision. Reviewing consumer feedback on independent review platforms, comparing total costs across several providers, and discussing options with a personal physician or urologist all contribute to a well-informed choice. Evaluating multiple sources is recommended before making any purchasing decision.

Summary of Key Considerations

Zealthy operates as a telehealth technology platform connecting men with independent licensed providers for prescription erectile dysfunction treatment. The platform offers both standard FDA-approved generic medications and its Hardies line of compounded sublingual formulations combining ingredients such as sildenafil, tadalafil, and oxytocin. As compounded prescription medications, Hardies have not undergone FDA review as finished products, while the individual active ingredients have established approvals and clinical research histories.

Pricing is subscription-based, combining medication costs with a recurring membership fee. Refund and cancellation terms should be reviewed carefully before committing, as prescription medication purchases are described as final sale. Safety information, contraindications, and potential side effects should be thoroughly discussed with a licensed healthcare provider before beginning any ED treatment.

Complete product details, current pricing, and published terms are available by viewing the current Zealthy ED offer (official Zealthy ED page).

Contact Information

Company: Zealthy (operated by FitRX, LLC)

Address: 30 Irving Place, Floor 7, New York, NY 10003

Phone: (877) 870-0323

Email: support@getzealthy.com

Website: https://try.getzealthy.com/ed/

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, healthcare, treatment, or diagnostic advice. The information presented is based on publicly available materials published by the company and should not be interpreted as a clinical recommendation. Consumers should consult a licensed healthcare provider before starting, changing, or discontinuing any prescription medication. All product claims, service descriptions, and pricing information are stated as presented by the company and have not been independently audited or verified unless specifically noted.

Compounded Medication Disclosure: Zealthy Hardies are compounded prescription medications. Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo FDA safety, effectiveness, or manufacturing review by the FDA. The individual active ingredients contained in Hardies formulations, including sildenafil, tadalafil, oxytocin, and vardenafil, have their own separate regulatory histories. The specific combinations, dosages, and sublingual delivery format used in Hardies products have not been evaluated by the FDA as finished products.

Results, Pricing, and Product Variability: Individual results from any erectile dysfunction treatment vary based on health status, underlying conditions, medication adherence, and other factors. Pricing, product availability, formulations, promotional offers, and subscription terms may change without notice. All details should be verified directly on the official website and with the prescribing provider before making any purchasing decision.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy or integrity of the information presented. Zealthy’s role as a telehealth platform facilitator does not constitute an endorsement of this article or any claims made in its promotion. The publisher is solely responsible for the content of this release.

CONTACT: Phone: (877) 870-0323
Email: support@getzealthy.com

BreezeMeds GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Pricing (From $199), FDA Regulatory Status Examined

BreezeMeds GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Pricing (From $199), FDA Regulatory Status Examined




BreezeMeds GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Pricing (From $199), FDA Regulatory Status Examined

A 2026 Informational Overview of the BreezeMeds Compounded GLP-1 Telehealth Weight Loss Platform, Semaglutide and Tirzepatide Medication Formats, Published Pricing Structure, 503A Compounding Pharmacy Framework, Clinical Research Boundaries, and Consumer Verification Considerations for Prescription Weight Management Programs

Marietta, GA, Feb. 27, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Compounded GLP-1 medications are prescription medications that require evaluation by a licensed clinician. Prescription approval is not guaranteed. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

If you have been researching GLP-1 weight loss medications in 2026, you already know how confusing the landscape has become. Telehealth platforms, compounded formulations, branded medications, shifting FDA guidance — there is a lot to sort through before you even get to whether a particular program makes sense for your situation. BreezeMeds is one of the platforms that comes up frequently in that research, and this overview is designed to help you understand what it offers, how the pricing works, where the regulatory environment stands right now, and what is worth verifying before you enroll.

BreezeMeds GLP-1 Weight Loss 2026 Compounded Semaglutide and Tirzepatide Telehealth Program, Pricing Starting at $199 (As Listed by the Company), FDA Regulatory Status, and What Consumers Should Verify Before Enrolling

These compounded formulations are not FDA-approved finished products, and individual outcomes are not guaranteed.

Current program details, medication availability, and pricing can be confirmed by viewing the current BreezeMeds offer (official BreezeMeds page).

What BreezeMeds Is: Platform Overview and Compounding Classification

BreezeMeds is a direct-to-consumer telehealth platform that connects individuals with licensed healthcare providers and partner compounding pharmacies for access to prescription GLP-1 weight loss medications. The platform is operated by Breezemeds, Inc. and offers compounded semaglutide injections, oral semaglutide, and oral tirzepatide according to its website.

The company describes the program as medically supervised weight loss personalized to each patient through a fully online process. If you are picturing a traditional doctor’s office experience, this is not quite that — it is a telehealth model where you complete a health assessment online, a licensed provider reviews your information and determines whether a prescription is appropriate, and medication ships to your door. That convenience is the core value proposition, but it also means understanding what you are getting and what the limitations are compared to in-person care.

The compounding distinction matters here. BreezeMeds’ medications are compounded formulations prepared by licensed pharmacies based on individual prescriptions. That means they are not FDA-approved as finished products. They have not been reviewed by the FDA for safety, effectiveness, or quality as finished formulations, and they are not generic equivalents of FDA-approved branded GLP-1 medications. The compounded nature of these medications does not, by itself, establish safety, effectiveness, or quality for any specific preparation. Consumers should rely on prescriber guidance and verify the dispensing pharmacy’s licensing and compliance disclosures.

BreezeMeds Medication Formats and Published Pricing

One area where BreezeMeds differentiates itself is format variety. According to the company’s website as of February 2026, the platform lists the following published starting prices by medication format:

Compounded Semaglutide Injection: starting at $199 per month, described as one injection per week.

Compounded Oral Semaglutide: starting at $299 per month, described as one dissolvable tablet per day.

Compounded Oral Tirzepatide: starting at $399 per month, described as one dissolvable tablet per day.

Sermorelin Injections: starting at $100, listed separately from the GLP-1 medication offerings.

The company advertises FSA and HSA eligibility and states that no subscription is required, according to promotional materials on the website. That said, pricing and program terms are subject to change and may vary based on clinical evaluation, dosing, and individual health factors. The latest details should be confirmed directly on the official website before enrolling.

Consumers can confirm current pricing and availability by viewing the current BreezeMeds offer (official BreezeMeds page), as pricing may change at any time.

The FDA Regulatory Landscape for Compounded GLP-1 Medications in 2026

This is arguably the most important section in this entire overview, because the regulatory environment has shifted in ways that directly affect anyone considering a compounded GLP-1 program right now — not just BreezeMeds, but every platform in this category.

Public FDA communications indicate the following: the semaglutide drug shortage was officially resolved in February 2025, and tirzepatide was removed from the shortage list in late 2024. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are generally prohibited from producing drugs that are essentially copies of commercially available FDA-approved products. During the shortage, that rule was relaxed. Now it is not.

There are limited exceptions under Section 503A that allow compounding when a prescriber determines a patient’s specific medical needs cannot be met by an FDA-approved drug. That is a narrower pathway than what existed during the shortage era, and it is the legal framework that platforms like BreezeMeds currently operate within.

Public reporting indicates the FDA sent warning letters to more than 50 entities in September 2025 related to GLP-1 compounding promotion and labeling concerns. Separately, the National Advertising Division reviewed advertising claims from several telehealth platforms offering compounded semaglutide and recommended modification or discontinuation of certain claims. As of February 2026, the FDA has signaled increased enforcement attention toward certain non-FDA-approved GLP-1 offerings, and the permissibility of compounding depends on patient-specific clinical need and evolving enforcement priorities.

What does this mean practically? It means the long-term availability of compounded GLP-1 programs is not guaranteed. Regulatory interpretations and enforcement priorities may change. Before enrolling in any platform, it is worth confirming the current program structure and regulatory posture with a healthcare provider.

How the BreezeMeds Program Works: The Three-Entity Model

One thing that often confuses people about telehealth weight loss platforms is that the company name on the website, the provider writing the prescription, and the pharmacy shipping the medication are typically three separate entities. Understanding this structure helps set realistic expectations about what you are actually signing up for.

BreezeMeds (Breezemeds, Inc.) functions as the telehealth technology platform. It provides the website, the intake process, customer support, and the coordination that connects you with a provider and pharmacy. It is not itself a healthcare provider.

Licensed Medical Providers are independent healthcare professionals who review patient health information and determine whether a GLP-1 prescription is clinically appropriate. The platform describes all providers as licensed and based in the United States. Prescription approval is never guaranteed — that decision rests entirely with the evaluating clinician.

Partner Compounding Pharmacies fulfill prescriptions written by the medical providers. According to the company’s website, these are 503A pharmacies that are primarily regulated by state boards of pharmacy and operate within a federal framework under the FD&C Act; FDA oversight and enforcement authority may apply depending on circumstances. Per the platform’s materials, medication ships with free, discreet delivery.

This three-entity structure is common in the telehealth category. Understanding who is responsible for prescribing, dispensing, and support can help set expectations, especially if questions about your prescription, your medication quality, or your refund come up later.

503A vs. 503B Pharmacies: What the Difference Means for Compounded GLP-1 Medications

For anyone doing their homework on a compounded medication platform, the terms 503A and 503B will come up, and understanding the difference is worth the time.

503A pharmacies are traditional state-licensed compounding pharmacies that prepare medications based on individual patient prescriptions — one prescription, one patient. They are primarily regulated by state boards of pharmacy, with FDA oversight and enforcement authority applicable under certain circumstances. 503B outsourcing facilities operate under a different federal framework, can produce compounded medications in larger batches, and are subject to more direct FDA oversight including current good manufacturing practice (cGMP) requirements.

BreezeMeds states its partner pharmacies are 503A facilities. The practical step is verifying the licensing status of the pharmacy that will prepare the medication. State board of pharmacy websites typically allow license verification by pharmacy name or license number.

Eligibility, Medical Review, and Why Prescription Approval Is Not Guaranteed

Not everyone who applies through a GLP-1 telehealth platform will receive a prescription. Prescription decisions should be based on clinician evaluation, medical history, and individual risk factors.

While BreezeMeds does not prominently list specific eligibility criteria on its main landing page, GLP-1 medications for weight management are generally prescribed based on factors including body mass index (BMI), the presence of weight-related health conditions, medication history, and individual clinical risk factors. The evaluating provider makes that determination based on the information you submit during the intake process.

If a provider determines you do not qualify, the company states that a full refund is issued. Consumers should confirm eligibility-stage refund timing in the platform’s published terms before paying, because refund terms can vary depending on how far into the process you have progressed when the determination is made.

It’s worth noting that a telehealth assessment, while convenient, may not capture everything an in-person exam would. If you have complex health conditions, are taking multiple medications, or have concerns about how a GLP-1 medication might interact with existing treatments, an in-person evaluation with your primary care provider may be a more thorough starting point.

Marketing Claims vs. Clinical Evidence: How to Interpret Published Weight Loss Statistics

This is the section where it’s especially important to be precise, because there’s a meaningful gap between what you’ll see on a platform’s marketing page and what has actually been established through clinical research.

What BreezeMeds’ Website States (Company Claims)

BreezeMeds’ website references several weight loss statistics in describing its program, including statements that patients may lose “15-20%” of body weight and related percentage-based milestones. The site also references figures such as “85% of patients lose 10% body weight,” “60% lose 15%,” and “50% lose 20%.” These figures are presented in the company’s marketing materials and have not been independently audited for this overview. Branded clinical trial results do not establish compounded product equivalence. Consumers evaluating these claims may wish to ask whether the platform’s figures are based on internal tracking, third-party audits, or generalized trial summaries. Nothing in these marketing statements should be interpreted as a guarantee of outcomes, and they do not substitute for prescriber-provided counseling.

The company also advertises that more than 50,000 patients have used the platform. This figure is presented by the company and has not been independently verified for this overview.

Some marketing materials in the GLP-1 telehealth category reference weekly weight loss ranges — for example, “1-2 pounds per week.” Statements like these should be interpreted as generalized promotional framing rather than guaranteed outcomes. Actual results vary substantially by individual, dose titration, adherence, baseline health, and clinician-directed care.

What FDA-Approved Trials Actually Studied (Branded Products)

Large clinical trials of FDA-approved branded injectable semaglutide reported that participants achieved an average body weight reduction of approximately 15% versus placebo over 68 weeks in the STEP-1 trial. Tirzepatide clinical trials (SURMOUNT-1) reported average body weight reduction of up to approximately 22% at the highest dosing level over 72 weeks. These trials were conducted under controlled conditions with specific FDA-approved branded formulations, extensive monitoring, and defined protocols.

Importantly, these results were observed using FDA-approved branded formulations under controlled trial protocols. They do not establish product-level effectiveness, equivalence, or quality for compounded preparations.

Why Compounded Formulations Are Not Automatically Comparable

The active ingredients in compounded GLP-1 formulations are the same as their branded counterparts, but that does not make them identical products. These preparations are not FDA-approved finished products and have not been evaluated for bioequivalence to branded medications. Formulation differences — including concentration, excipients, and pharmacy-specific preparation methods — may exist between compounded and branded versions.

This is not meant to be alarming. It’s meant to be accurate. The ingredient-level research is real, but extending branded trial conclusions directly to compounded formulations goes beyond what the evidence supports. That distinction matters for making an informed decision about any compounded GLP-1 program.

Comparing GLP-1 Access Pathways in 2026

For those weighing their options, it helps to understand the three main ways people access GLP-1 weight loss medications right now, because they differ in regulatory status, cost, and the level of clinical oversight involved.

FDA-approved branded GLP-1 medications through traditional healthcare have undergone the FDA’s full review process for safety, efficacy, and manufacturing quality. They carry specific FDA-approved indications and extensive clinical trial data. Cash-pay list prices for branded GLP-1 medications can exceed $1,000 per month without insurance, though manufacturer savings programs and insurance coverage may reduce out-of-pocket costs for eligible patients.

Telehealth platforms offering compounded GLP-1 medications — including BreezeMeds — facilitate access through licensed compounding pharmacies based on individual prescriptions. Pricing across this category typically ranges from $199 to $499 per month depending on format and dosing. These medications are not FDA-approved as finished products and have not been evaluated for bioequivalence to branded formulations.

In-person physician-prescribed treatment may include either branded or compounded medications and often provides more comprehensive monitoring — lab work, physical examinations, and ongoing follow-up that telehealth-only models may not include in their standard programs.

What to Ask a Telehealth GLP-1 Provider Before Paying

Before committing financially to any telehealth GLP-1 program, there are several questions worth asking that can help you evaluate whether the platform is a good fit for your situation.

Which pharmacy will compound my medication, and can I verify its license? Knowing the pharmacy name and checking its status through your state board of pharmacy takes a few minutes and gives you an independent verification point beyond what the platform itself tells you.

What happens if the prescriber determines I’m not eligible? Understanding the refund process and timeline before you pay is important, because policies can differ depending on where you are in the enrollment process when a decision is made.

What ongoing monitoring is included after the initial prescription? Some platforms include regular provider check-ins, dosing adjustments, and messaging access. Others provide the initial prescription with limited follow-up. The level of ongoing oversight matters, especially during dose titration.

Is this a subscription, and what are the auto-renewal terms? Even if a platform advertises “no subscription required,” it’s worth confirming the exact payment structure, whether charges recur automatically, and what the cancellation process looks like.

What is the compounded formulation, and how does it differ from the branded product? You’re entitled to understand what you’re receiving. A reputable platform should be transparent about whether its formulations include additional ingredients (such as B12 or other compounds) and how the preparation differs from FDA-approved versions.

Refunds, Cancellation, and Shipping: Where Consumers Commonly Have Questions

Refund and cancellation terms are one of the areas where consumers across the telehealth GLP-1 category most frequently report confusion. The specifics vary by platform, and BreezeMeds is no exception.

The company states that if a provider determines you do not qualify for a prescription, a full refund is issued. The specific timing and process for that refund should be confirmed on the official website before enrolling. What is less clear from publicly available materials is what happens if you qualify and receive medication but later want to discontinue — whether partial refunds are available, whether unused medication can be returned, and what the specific cancellation window looks like.

On shipping, the company advertises free, discreet delivery. For shipped medications, it may be worth confirming whether temperature controls apply to the specific formulation being dispensed, as some compounded injectable preparations may have storage and handling requirements during transit.

A practical consideration: read the full terms of service before paying, not after. The refund section is typically the most consequential part of any telehealth enrollment agreement.

Safety Considerations and Adverse Event Awareness

GLP-1 receptor agonists carry known side effect profiles that are worth understanding before beginning any treatment, whether through branded or compounded formulations. Commonly reported side effects in clinical trials of FDA-approved GLP-1 medications include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These gastrointestinal effects are typically most pronounced during initial dosing and the titration period as the body adjusts.

More serious potential risks discussed in FDA-approved prescribing information for branded GLP-1 medications include pancreatitis, gallbladder problems, kidney issues, and potential thyroid tumor risk based on animal studies. GLP-1 medications should not be used during pregnancy or breastfeeding. Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications.

If you experience side effects while on a compounded GLP-1 medication, the prescribing clinician and the dispensing pharmacy are your first points of contact. For severe or emergency symptoms — difficulty breathing, severe abdominal pain, signs of allergic reaction — seek emergency medical care immediately regardless of your telehealth program status. This overview is not exhaustive and does not replace the safety information provided with your prescription.

Consumer Questions About BreezeMeds

Is BreezeMeds a healthcare provider or a telehealth platform?

Based on publicly available information, BreezeMeds operates as a telehealth platform that connects consumers with licensed healthcare providers. Medical decisions and prescribing are handled by independently licensed clinicians, not by the platform itself. This distinction can be confirmed in the company’s terms of service.

Are BreezeMeds medications the same as FDA-approved branded GLP-1 medications?

They are not the same products. The compounded versions contain the same active ingredient (semaglutide or tirzepatide) but are prepared by compounding pharmacies and have not been evaluated by the FDA as finished products. Differences in formulation, concentration, and preparation methods may exist between compounded and FDA-approved branded versions.

What does “no subscription required” mean in practice?

The company’s promotional materials state that no subscription is required. It’s worth confirming whether this means single purchases are available, whether ongoing treatment involves recurring payments, and what the specific payment and renewal terms are before committing financially.

Does BreezeMeds accept insurance?

The company advertises FSA and HSA eligibility. Whether the platform accepts traditional health insurance or operates primarily on a cash-pay basis should be confirmed directly, along with FSA/HSA eligibility through your specific plan administrator.

What is the current regulatory status of compounded GLP-1 medications?

As of February 2026, the FDA has resolved the semaglutide drug shortage and has signaled increased enforcement attention toward certain non-FDA-approved GLP-1 products. The permissibility of compounding depends on patient-specific clinical need and evolving enforcement priorities. Current regulatory status should be verified with a healthcare provider and the platform before enrolling, as this landscape can change.

How does BreezeMeds pricing compare to branded GLP-1 medications?

Published starting prices range from $199 to $399 per month depending on medication format. Cash-pay list prices for FDA-approved branded GLP-1 medications can exceed $1,000 per month without insurance, though manufacturer savings programs and insurance coverage may reduce branded costs for eligible patients. Price alone should not be the determining factor — regulatory status, clinical oversight, and pharmacy quality all factor into the overall value equation.

What should I do if I experience side effects?

Contact the prescribing clinician and the dispensing pharmacy as your first step. For severe symptoms — difficulty breathing, severe abdominal pain, signs of allergic reaction — seek emergency medical care immediately. You can also report adverse events to the FDA through its MedWatch reporting system.

Can GLP-1 medications interact with other prescriptions I’m taking?

GLP-1 medications may interact with other prescriptions, including diabetes medications, blood thinners, and certain oral medications whose absorption may be affected. It is important to disclose your complete medication list, including over-the-counter supplements, during the intake assessment. The prescribing clinician should evaluate potential interactions as part of the consultation.

Additional Consumer Research

Additional independent research across multiple consumer publications and medical information sources may provide broader perspective on compounded GLP-1 telehealth platforms, prescription weight loss medications, and the current regulatory environment. Evaluating multiple sources can be helpful before making any enrollment or purchasing decision involving prescription medications.

Summary of Key Considerations

BreezeMeds operates as a telehealth platform offering compounded GLP-1 weight loss medications with published pricing starting at $199 per month for injectable semaglutide, $299 for oral semaglutide, and $399 for oral tirzepatide, according to the company’s website as of February 2026. The platform uses a three-entity model — telehealth platform, independent licensed providers, and 503A partner pharmacies — to facilitate access to prescription weight management medications through a fully online process.

Compounded GLP-1 medications are not FDA-approved finished products and have not been evaluated by the FDA for safety, effectiveness, or quality as finished formulations. The regulatory landscape for compounded GLP-1 access has narrowed since the FDA resolved the semaglutide shortage in 2025, and current permissibility depends on patient-specific clinical need and evolving enforcement priorities. Verifying pharmacy licensing, provider credentials, refund terms, and the current regulatory posture of any platform may be worth considering before enrolling.

Complete product details, current pricing, and published terms are available by viewing the current BreezeMeds offer (official BreezeMeds page).

Contact Information

Company: BreezeMeds

Website: https://www.breezemeds.com/

Email: support@breezemeds.com

Operated by: Breezemeds, Inc.

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, financial, or legal advice. All product details, pricing, program descriptions, and company claims referenced in this article are stated as presented by the company’s publicly available materials and have not been independently audited or verified unless specifically noted. All details should be confirmed directly on the official website and with a licensed healthcare professional before making any purchasing or treatment decisions.

Compounded Medication and FDA Regulatory Notice: The medications discussed are compounded prescription medications prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They are prepared using active pharmaceutical ingredients under the direction of a prescribing clinician. Compounded drugs are not generic equivalents of FDA-approved branded medications. Whether an FDA-approved option is appropriate should be discussed with a licensed clinician. As of February 2026, the FDA has resolved the semaglutide drug shortage and has signaled increased attention to certain non-FDA-approved GLP-1 offerings. The permissibility of compounding depends on patient-specific clinical need and evolving enforcement priorities. Regulatory status is subject to change.

Results, Pricing, and Product Variability: Individual results vary based on adherence, baseline health, clinical factors, and clinician-directed dosing. Weight loss statistics referenced on the company’s website appear to reflect general GLP-1 clinical trial data from FDA-approved branded medications studied under controlled conditions and do not constitute BreezeMeds-specific outcome data unless independently verified. Branded trial results do not establish product-level effectiveness, equivalence, or quality for compounded preparations. Pricing, program terms, medication availability, and promotional offers are subject to change without notice. Current details should be verified through the official website before enrolling.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. The publisher is responsible for the content of this article. The telehealth platform’s role as the service provider does not constitute an endorsement of this article or any claims made in its promotion.

CONTACT: support@breezemeds.com

ReduBurn Thermogenic Resistance Claims Evaluated: Latest Report on Ingredients, Pricing, Refund Terms, and What Consumers Should Verify Before Buying

ReduBurn Thermogenic Resistance Claims Evaluated: Latest Report on Ingredients, Pricing, Refund Terms, and What Consumers Should Verify Before Buying




ReduBurn Thermogenic Resistance Claims Evaluated: Latest Report on Ingredients, Pricing, Refund Terms, and What Consumers Should Verify Before Buying

Informational 2026 customer report evaluates ReduBurn marketing claims, ingredient transparency, thermogenic resistance framing, pricing structure, published refund terms, and consumer due diligence for men and women.

Aurora, CO, Feb. 27, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This report is an informational overview and does not constitute medical, nutritional, or health advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision. Individual results from any dietary supplement vary, and this report does not guarantee any specific health outcome.

Consumer searches for natural weight management supplements have continued to increase throughout 2026, with growing interest in plant-based formulas marketed toward metabolic support and appetite management. Among the products drawing attention in this category is ReduBurn, a dietary supplement positioned as a thermogenic support formula for men and women seeking non-prescription supplement options to discuss alongside broader weight-management approaches.

ReduBurn Thermogenic Resistance Claims Evaluated Latest Report on Ingredients, Pricing, Refund Terms, and What Consumers Should Verify Before Buying

This report evaluates publicly available marketing claims about ReduBurn, including ingredient transparency, pricing structure, and published refund policy terms. Any mechanism references — including thermogenic or metabolic “resistance” framing — are presented as described by the company and should be verified directly on the official product page.

Current product details, pricing, and terms can be confirmed by viewing the current ReduBurn offer (official ReduBurn page).

What Is ReduBurn?

ReduBurn is a dietary supplement sold in capsule form exclusively through its official website. The company describes it as a natural formula combining plant-based ingredients intended to support the body’s metabolic pathways. Its marketing positions the product around four primary mechanisms: appetite control, metabolic rate support, body composition support positioning, and energy balance related to how the body processes food.

The product is marketed toward adults — both men and women — who’ve experienced difficulty with weight management despite changes to diet and exercise routines. The recommended dosage listed on the product page is one capsule daily. ReduBurn does not require a prescription and is sold as a direct-to-consumer dietary supplement.

Like all dietary supplements sold in the United States, ReduBurn has not been evaluated by the U.S. Food and Drug Administration for the purpose of diagnosing, treating, curing, or preventing any disease. The FDA does not approve dietary supplements in the same manner it approves pharmaceutical drugs, and it’s worth keeping this distinction in mind when evaluating any supplement’s marketing claims.

ReduBurn Claims Evaluated: Thermogenic and Metabolic Resistance Framing

Some supplement brands describe a concept sometimes referred to in marketing as “thermogenic resistance” — the idea that the body may not respond to certain diet or thermogenic strategies the way consumers expect. This report treats that framing as a marketing concept rather than a medical diagnosis, and it’s worth evaluating it on those terms.

The ReduBurn product page references the role of internal body temperature and metabolic function as part of its scientific positioning. The product page frames the formula around thermogenic and metabolic support concepts. These descriptions are presented by the seller and should be interpreted as marketing language rather than independently validated clinical outcomes.

Consumers researching terms such as “ReduBurn effectiveness,” “does ReduBurn work,” or “ReduBurn thermogenic claims” should understand that marketing language describing metabolic support represents the company’s characterization of its product — not independently validated clinical outcomes. The distinction between a company’s marketing framing and verified clinical evidence is one of the most important factors in evaluating any dietary supplement.

This report does not assess whether ReduBurn has utility as a metabolic support supplement. It focuses on clarifying how the product’s performance-related marketing language should be interpreted by consumers making purchasing decisions.

What “Thermogenic” Means in Supplement Marketing

The term “thermogenic” appears frequently in weight management supplement marketing. In a biological context, thermogenesis refers to the body’s production of heat, which is a normal part of metabolism. Some supplement brands use “thermogenic” to suggest that their formulas may support this natural process, potentially influencing how the body expends energy.

However, the use of “thermogenic” in supplement marketing doesn’t guarantee a specific outcome. Individual responses to thermogenic ingredients vary widely, and the presence of a thermogenic label on a supplement doesn’t mean the product has been clinically demonstrated to produce measurable changes in metabolic rate for all users. Consumers should treat “thermogenic” as a category descriptor used in marketing, not as a promise of results.

ReduBurn Ingredient Transparency: What Consumers Should Verify

One area worth paying close attention to is ingredient specificity. The official ReduBurn website at reduburn.com displays its ingredient information primarily through product label images rather than itemized text lists. While the company references a blend of natural ingredients and describes their intended functions, the full supplement facts panel — including exact ingredient names, dosage amounts, proprietary blend disclosures, inactive ingredients, and allergen information — is not presented in searchable text format on the main product page.

Consumers researching “ReduBurn ingredients,” “ReduBurn formula,” “ReduBurn supplement facts,” or “what is in ReduBurn” should confirm specific ingredient names, concentrations, and sourcing directly from the product label or by contacting the seller’s support team. This is standard due diligence for any supplement purchase, not a concern specific to ReduBurn.

Why Image-Based Ingredient Labels Matter for Consumer Research

When a supplement brand displays its ingredient label as an image rather than in searchable text, it can make independent research more difficult for consumers. Text-based ingredient disclosures allow shoppers to quickly cross-reference specific compounds, review label-listed amounts for personal due diligence, and check for potential allergens or interaction concerns with a clinician. Image-only labels require shoppers to read the physical product packaging after purchase — or to contact the seller’s support team directly — to access this information beforehand.

This isn’t unique to ReduBurn; many direct-to-consumer supplement brands use image-based labels on their sales pages. Still, anyone who prioritizes ingredient transparency may want to request a text-based supplement facts breakdown from the seller before committing to a purchase, particularly when evaluating products in the weight management category where ingredient quality and dosing can vary significantly between brands.

For any dietary supplement, third-party testing certifications, published ingredient sourcing documentation, and transparent dosage disclosure are considered hallmarks of consumer-friendly manufacturing practices. The company states that ReduBurn is manufactured in an FDA-registered, GMP-certified facility in the United States and describes the product as non-GMO, gluten-free, and non-habit forming. Consumers may wish to inquire whether third-party testing certificates or published clinical references supporting the formula are available before purchase.

ReduBurn Pricing Verified

ReduBurn is sold exclusively through its official website and is not available through major third-party retailers such as Amazon or Walmart, or in physical stores, according to the seller. As listed on the official website at the time of this report, the product is offered in multiple purchase tiers, including a single-bottle option and multi-bottle packages, with per-bottle pricing decreasing at higher quantities.

The site lists a single-bottle option at $69, a two-bottle package at $79 per bottle, a three-bottle package at $59 per bottle, and a six-bottle package at $49 per bottle. Shipping terms vary by tier, with free U.S. shipping listed for the three-bottle and six-bottle options. The single-bottle option is described as a monthly subscription with recurring delivery. Consumers who prefer a one-time purchase should confirm the billing and cancellation terms listed at checkout.

Because pricing, availability, and shipping terms can change at any time without notice, it’s worth confirming the current offer directly on the official page before purchasing. Current pricing and availability can be verified by viewing the current ReduBurn offer (official ReduBurn page), as pricing may change at any time.

ReduBurn Refund Policy Terms: What the Pages Say

This is an area worth reading carefully before ordering. The ReduBurn sales page prominently displays a 180-day money-back guarantee alongside each pricing tier. However, the published refund policy section within the website’s legal terms references a 60-day window to request a refund.

Because the sales page guarantee language and the formal refund policy language reference different timeframes, consumers may wish to review both sections carefully and contact customer support for clarification on the applicable return window before ordering. The seller’s published policy indicates that refund requests should be directed to support@reduburn.com or by phone, and that processing times may vary depending on the buyer’s financial institution and payment method.

This report doesn’t characterize either timeframe as more authoritative than the other — it simply notes that the two published timeframes don’t match, which makes direct verification with the seller the recommended step before purchase.

ReduBurn and Weight Management Outcomes Context

Consumers researching whether ReduBurn works or seeking information about expected results should understand the broader context of dietary supplement outcomes. The U.S. Federal Trade Commission and the FDA have consistently emphasized that individual results from dietary supplements vary significantly based on genetics, baseline health, diet, physical activity, sleep quality, and metabolic differences between individuals.

The official site includes customer testimonials describing individual experiences. Testimonials reflect personal opinions and may not represent typical outcomes. This report doesn’t independently verify testimonial claims, and they’re best treated as anecdotal rather than clinical evidence.

No published clinical trials specific to the finished ReduBurn formula were identified during the preparation of this report. Consumers evaluating any weight management supplement should consider that sustainable weight management is broadly supported by evidence-based practices including balanced nutrition, regular physical activity, adequate sleep, and stress management. Supplements, when used, are generally considered complementary to these foundational practices rather than replacements for them.

Safety and Who Should Consult a Clinician First

ReduBurn’s marketing states that the product is made from natural, non-GMO ingredients and manufactured in a GMP-certified facility. That said, “natural” doesn’t automatically mean appropriate for every individual, and anyone with specific health considerations should take extra care.

Individuals with pre-existing medical conditions — particularly those related to metabolic health, cardiovascular function, or hormonal balance — should consult a physician or qualified healthcare provider before adding any supplement to their routine. This also applies to individuals currently taking prescription medications, as ingredient interactions can vary based on the specific compounds involved.

Women who are pregnant or nursing should consult a healthcare professional before use. The company’s own marketing includes similar guidance on its official website, and this report reinforces that recommendation as standard practice for any dietary supplement in this category.

Consumer Checklist Before Buying ReduBurn

Verify the full ingredient list. Confirm exact ingredient names, dosage amounts, proprietary blend disclosures, and allergen information directly from the product label or seller support — not just from the marketing page.

Clarify the refund timeframe. Contact the seller before purchasing to confirm whether the 180-day or 60-day window applies to your order, and ask about any conditions for returns.

Ask about third-party testing. Some buyers look for third-party testing — for example, programs such as NSF or USP in other supplement contexts — as an added quality signal, though availability varies by brand.

Look for published research. Products that reference clinical studies should be able to point to specific, peer-reviewed publications — not just general language about “studies show.”

Talk to your doctor. This is especially important if you have existing health conditions, take medications, or are pregnant or nursing.

Confirm pricing and subscription terms. If the single-bottle option is a recurring subscription, verify the cancellation process and billing cycle before placing your order.

Weight Management Supplements in 2026: Category Context

The dietary supplement market for weight management continues to expand, with consumers increasingly seeking natural, plant-based alternatives to pharmaceutical interventions. Products in this category typically position themselves around mechanisms such as thermogenesis support, appetite regulation, metabolic rate optimization, and energy balance.

The supplement industry operates under a different regulatory framework than pharmaceuticals. Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, manufacturers are responsible for ensuring their products are safe and that label claims are truthful, but they are not required to obtain FDA pre-market approval. The FDA may take enforcement action against supplements found to be unsafe or mislabeled after they reach the market.

For anyone navigating this landscape, comparing multiple products, reviewing independent testing results where available, and consulting qualified healthcare professionals before beginning any new supplement regimen are all recommended practices.

Who Might Consider ReduBurn in 2026

Based on the company’s marketing, ReduBurn appears to be positioned toward adults — both men and women, particularly those aged 35 and older — who’ve experienced difficulty managing weight through diet and exercise alone. The product’s framing suggests it’s intended as a natural, non-prescription supplement to complement existing wellness practices, not replace medical treatment.

Anyone considering ReduBurn should weigh whether the product’s published ingredient information, pricing, and guarantee terms align with their personal health goals and budget. It’s worth remembering that no dietary supplement is a substitute for medical treatment. Anyone experiencing significant or unexplained weight changes should consult a healthcare provider to rule out underlying medical conditions before pursuing supplement-based approaches.

Consumer Questions About ReduBurn

What is ReduBurn?

ReduBurn is a capsule-form dietary supplement sold through its official website. The company markets it as a natural formula containing plant-based ingredients designed to support metabolism, appetite control, and fat metabolism for men and women.

Is ReduBurn FDA approved?

No. Dietary supplements in the United States are not subject to FDA approval in the way prescription or over-the-counter drugs are. ReduBurn’s official site states it is manufactured in an FDA-registered, GMP-certified facility, which refers to the manufacturing environment rather than approval of the product itself.

What ingredients are in ReduBurn?

The product page lists a blend of natural ingredients targeting metabolic support, appetite control, and fat metabolism. Specific ingredient names, dosages, and supplement facts are displayed on the product label image. It’s worth verifying the full ingredient list directly on the official website or from the product packaging.

What is thermogenic resistance, and does ReduBurn address it?

Some weight management brands reference “thermogenic resistance” as a marketing concept describing why certain individuals may not respond to standard diet or thermogenic strategies. This is a marketing framing used in supplement positioning — not a recognized medical diagnosis. ReduBurn’s marketing positions the product as supporting the body’s natural thermogenic processes, but this claim should be evaluated as marketing language, not a clinically validated outcome.

How much does ReduBurn cost?

As listed on the official website, pricing ranges from $49 to $69 per bottle depending on the package selected, with per-unit pricing decreasing at higher quantities. Pricing may change without notice, so it’s worth verifying directly on the official page.

What is ReduBurn’s refund policy?

The sales page displays a 180-day money-back guarantee, while the published refund policy terms reference a 60-day return window. It’s worth contacting the seller directly to clarify which timeframe applies before purchasing.

Where can I buy ReduBurn?

The seller states that ReduBurn is available exclusively through its official website and is not sold through Amazon, retail stores, or other third-party platforms.

Does ReduBurn require a prescription?

No. ReduBurn is sold as a direct-to-consumer dietary supplement and does not require a prescription or medical authorization to purchase.

Is ReduBurn safe?

Per the product’s marketing, ReduBurn is made from natural, non-GMO ingredients in a GMP-certified facility. Individual responses to any supplement can vary. Anyone with pre-existing conditions, those taking medications, or women who are pregnant or nursing should consult a physician before use.

Who is behind ReduBurn?

ReduBurn is marketed through reduburn.com. The website’s published terms reference an entity called Nature’s Formulas in connection with the product’s mobile communications services. Orders are processed through BuyGoods Inc., a third-party payment processor.

Are the testimonials on the ReduBurn website verified?

Customer testimonials labeled as verified purchases appear on the official website. This report has not independently verified those testimonials. Individual testimonials represent personal experiences and may not reflect typical results.

How should I evaluate supplement marketing claims?

Look for specific, peer-reviewed clinical research cited by the brand. Review any peer-reviewed research the company cites, if provided, and consult a clinician for individualized guidance. Check for third-party testing certifications. Treat phrases like “clinically tested ingredients” differently from “clinically tested product” — the distinction matters. When in doubt, consult a healthcare professional.

Additional Consumer Research

Additional independent research across multiple consumer publications and health information resources may provide broader perspective on this product category. Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also find it helpful to review general guidance on dietary supplement evaluation published by organizations such as the National Institutes of Health Office of Dietary Supplements.

Summary of Key Considerations

ReduBurn is a dietary supplement positioned within the natural weight management category, marketed toward men and women seeking plant-based metabolic and appetite support. The company’s marketing includes thermogenic resistance framing and mechanism claims that this report has evaluated as marketing language rather than independently verified clinical outcomes. Ingredient details are primarily displayed in image format, and it’s worth verifying the full supplement facts panel before purchasing. The refund policy timeframe discrepancy between the sales page and formal terms warrants direct clarification with the seller.

Complete product details, current pricing, and published terms are available by viewing the current ReduBurn offer (official ReduBurn page).

Contact Information

Product: ReduBurn

Official Website: reduburn.com

Return Address: 19655 E 35th Drive. Suite 100, Aurora, CO 80011

Customer Support Email: support@reduburn.com

Customer Support Phone: +1 (970) 406-7582

Payment Processor: BuyGoods Inc., 1000 North West St., Suite #1200, Wilmington, DE 19801

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, nutritional, health, or legal advice. The information presented has not been independently audited or verified unless specifically noted. All product details, ingredient descriptions, mechanism claims, pricing, and guarantee terms are stated as presented by the seller and should be confirmed directly on the official product website before any purchasing decision.

Health and Dietary Supplement Notice: Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. The statements made by the product’s seller regarding ReduBurn have not been evaluated by the U.S. Food and Drug Administration. Individual results vary based on numerous factors including diet, exercise, genetics, and baseline health. Consumers should consult a qualified healthcare professional before beginning any new supplement, particularly those with pre-existing medical conditions, individuals taking prescription medications, or women who are pregnant or nursing.

Results, Pricing, and Product Variability: Product pricing, availability, ingredient formulations, and promotional terms may change without notice. All information is accurate as of the publication date based on publicly available materials. Consumers should verify current details through the official website and the payment processor before completing a purchase.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. BuyGoods Inc.’s role as payment processor does not constitute an endorsement of the product or any claims made in its promotion. The publisher is responsible for the content of this article. The presence of affiliate links does not influence the informational content or editorial perspective of this report.

CONTACT: Email: support@reduburn.com
Phone: +1 (970) 406-7582

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older




FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

  • The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval
  • Commercial availability expected during early part of Q2 2026
  • Rare Pediatric Disease Priority Review Voucher granted in connection with approval
  • Ascendis to host investor conference call Monday, March 2, at 8:00 am ET

COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA’s Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growth in children 2 years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic exposure to CNP over the weekly dosing interval. Continued approval for this indication, which was based on an improvement in annualized growth velocity (AGV), may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Achondroplasia is a rare genetic condition causing skeletal dysplasia and, for many affected individuals, an increased risk of muscular, neurological, and cardiorespiratory complications. YUVIWEL is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia.

“The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said Carlos A. Bacino, MD, FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital. “My goal is to help children and parents develop care plans tailored to their individual needs and objectives, and I look forward to adding YUVIWEL to my discussions with them.”

“Little People of America, the largest national advocacy and support organization for people with dwarfism, is committed to ensuring that the voices of people with dwarfism remain central in conversations about research and medical options such as YUVIWEL,” said the Board of Directors of Little People of America. “We champion dwarf and disability pride, advocate for inclusion and respect, and foster open dialogue across diverse perspectives. Our goal is to empower individuals and families to make healthcare decisions that reflect their own values and experiences, while pushing for research efforts and new treatment options such as this that could have the potential to support outcomes that truly matter to our community.”

The FDA based its approval of YUVIWEL on their review of the clinical package for TransCon CNP submitted with the Company’s New Drug Application, which included safety and efficacy data from three randomized, double-blind, placebo-controlled clinical trials and up to three years of open-label extension data. The pivotal ApproaCH Trial data is available in JAMA Pediatrics.i

“We are confident in YUVIWEL’s potential to transform the treatment of achondroplasia and are deeply grateful to patients, clinicians, and advocates for their many contributions to this important milestone,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “We have listened to advocacy groups for people with dwarfism to ensure we address what the community actually cares about. This reflects our ongoing commitment to pursue outcomes that patient communities have told us are important to them, and gives the achondroplasia community a new way to look at the promise of pharmacological treatment options.”

Ascendis expects to make YUVIWEL available through prescribing physicians in the United States during the early part of the second quarter of 2026. Ascendis plans to offer a suite of patient services for YUVIWEL through its U.S. Ascendis Signature Access Program (A.S.A.P.), including support navigating the treatment journey and financial assistance programs for eligible patients.

With this approval, the FDA also issued a Rare Pediatric Disease Priority Review Voucher (PRV), which confers priority review to a subsequent drug application that would not otherwise qualify for priority review. This program is designed to encourage development of new drugs and biologics for the prevention or treatment of rare pediatric diseases.

Conference Call and Webcast Information
Ascendis will host a call to review the FDA approval of YUVIWEL on Monday, March 2, 2026, at 8:00 am ET. Those who would like to participate may access the live webcast here or register in advance here. The link to the live webcast and slides will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.

The following information is intended for the U.S. audience only:
USE AND IMPORTANT SAFETY INFORMATION

What is YUVIWEL?
YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of YUVIWEL?
YUVIWEL may cause serious side effects, including risk of low blood pressure. If your child experiences a decrease in blood pressure or symptoms of low blood pressure (dizziness, feeling tired, and/or nausea) while being treated with YUVIWEL, call your child’s healthcare provider.

The most common side effects of YUVIWEL include injection site reactions (redness, itching, skin discoloration, bleeding, swelling, bruising, pain, and blistering).

Before you give YUVIWEL to your child, tell the healthcare provider about all of your child’s medical conditions, including if they:

  • have kidney problems
  • are pregnant or plan to become pregnant. It is not known if YUVIWEL will harm the unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if YUVIWEL passes into breast milk

Tell the healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

These are not all of the possible side effects of YUVIWEL. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.

Please see full Prescribing Information for YUVIWEL.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, and is associated with an increased risk of muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia can vary from individual to individual and across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and reduced stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; some of which persist or worsen in adulthood. These medical complications can affect quality of life, physical well-being, influenced by a range of clinical, social, and individual factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) the expected timing for the commercial availability of YUVIWEL, (ii) the continued approval for the indication, (iii) the suite of patient services Ascendis plans to offer for YUVIWEL, (iv) YUVIWEL’s potential to transform the treatment of achondroplasia, (v) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients’ lives and (vi) Ascendis’ use of TransCon to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, TransCon, and YUVIWEL are trademarks owned by the Ascendis Pharma group. © February 2026 Ascendis Pharma A/S.

Investor Contacts:
Chad Fugere
Ascendis Pharma
ir@ascendispharma.com
Media Contact:
Melinda Baker
Ascendis Pharma
media@ascendispharma.com
   
Patti Bank
ICR Healthcare
+1 (415) 513-1284
patti.bank@icrhealthcare.com
 
   

i Savarirayan R, McDonnell C, Bacino CA, et al. JAMA Pediatr 2026;180(1):18–25. Published online November 17, 2025. doi:10.1001/jamapediatrics.2025.4771

OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.




OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) — OpGen, Inc. (OTC: OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company’s business to the digital investment banking and financial technology sectors. The name “CapForce” represents the “Force of Capital,” symbolizing the Company’s conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their weight to enter the mid-cap or even large-cap universe. In connection with the name change, the Company expects to change its ticker symbol to “CFOR.”

About CapForce Inc.

CapForce Inc. (Clarksburg, Md., U.S.A.), along with its subsidiaries CapForce International Holdings Ltd. and iCapX Sdn. Bhd., provides fintech-enabled digital investment banking services for global high-growth mid-sized private companies seeking public market listings and other capital markets advisory services, of listing market capitalization value in the range of $1 billion to $10 billion, with its key focus on small-cap and mid-cap listing stocks underserved by bulge bracket investment banks. In furtherance of such core strategy, CapForce Inc. is pursuing fintech-enabled and AI-powered asset and wealth management services for its core investment banking clients across the world with the development of a digital investment banking platform designed to facilitate cross-border securities activities, AI-powered robo-advisory services, and technology-driven capitalization table management solutions. The timing and implementation of these initiatives are subject to market conditions, regulatory approvals, and other relevant factors. CapForce Inc.’s controlling shareholder, AEI Capital Group, is an Asia-based alternative asset management group with groupwide AUM exceeding $7 billion, focused on global growth equity (private and public markets) as its core strategies, along with other satellite strategies in furtherance of its core strategies including private credit, hedge funds, funds-of-funds and real estate, having its footprints in Hong Kong, Kuala Lumpur, Singapore, London and Washington D.C.

For more information, please visit https://capforce.opgen.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are intended to qualify for the safe harbor from liability established thereunder. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond the Company’s control, and which may cause results to differ materially from expectations, including risks regarding the implementation and execution of operational, legal, and administrative changes associated with the name change, the effectiveness of the Company’s rebranding efforts, potential confusion among customers, partners, or investors, and costs associated with the rebranding process. For further discussion of factors that could materially affect the outcome of the Company’s forward-looking statements and its future results and financial condition, see “Risk Factors” in Part I, Item 1A, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its other reports filed with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CapForce Inc.:
Christian-Laurent Benoit Bonte
Chief Executive Officer
InvestorRelations@opgen.com

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock.

These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys’ Board of Directors and made as an inducement material to employment to individuals hired by Femasys. The stock options will vest as to 25% of the shares underlying the stock option on the first anniversary of the commencement of employment, with the remaining shares vesting 25% each year over the following three years, subject to continued employment with Femasys. Femasys provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm®, a CLIA waived sperm preparation and analysis product line; and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.1

FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com